



POSTER PRESENTATIONS
presented in Boston
and available on the CTAD23
digital platform

Listing of CTAD23 POSTERS

All posters are available in Pdf format
at all times on the CTAD23 digital platform.

Posters presented [remotely](#)
are indicated with this icon :



THEME: Clinical Trials: Methodology

THEME: Clinical Trials: Results

THEME: Clinical Trials: Imaging

THEME: Clinical Trials: Biomarkers including plasma

THEME: Clinical Trials: Cognitive and Functional Endpoints

THEME: Cognitive assessment and clinical trials

THEME: Behavioral disorders and clinical trials

THEME: Health economics and clinical trials

THEME: Epidemiology and clinical trials

THEME: Animal Model

THEME: New Therapies and Clinical Trials

THEME: Proof of Concept/Translational research

THEME: Digital health/E-trials

THEME: Beyond Amyloid and Tau

P001 to P030 & LP001 to LP016

P031 to P045 & LP017 to LP034

P046 to P063 & LP035 to LP042

P064 to P097 & LP043 to LP060

P098 to P117 & LP062 to LP069

P118 to P137 & LP070 to LP080 & LP121 to LP123

P138 to P140 & LP124 to LP126

P141 to P143

P144 to P150 & LP082 to LP083 & LP127 to LP128

P151 to P152 & LP084 to LP089

P153 to P158 & LP090 to LP097 & LP129 to LP130

P159 to P178 & LP098 to LP108

P179 to P192 & LP109 to LP117 & LP131 to LP133

P193 to P204 & LP118 to LP120

THEME: Clinical Trials: Methodology

- P001** **Variation in the mini-mental state examination in subjects with suspected mild to moderate Alzheimer's disease: Implications for clinical trial designs**
James Rock¹, Jessie Nicodemus-Johnson², Holly Wood², Fred Kim¹, Jongkyi Kim³, Yoon-Seok Chun³, Suzanne Hendrix²
¹AriBio - San Diego (United States), ²Pentara - Mill Creek (United States), ³AriBNC - Gyeonggi-Do (United States)
- P002** **Communicating Topline Trial Results to Participants and Study Partners in a Preclinical Alzheimer's Disease Study**
Taylor Clanton¹, Joshua D. Grill², Jason Karlawish³, Karen Chilcott Holdridge⁴, Roy Yaari⁴, Rema Raman¹, Sarah Walter¹, Elizabeth Shaffer¹, Paula J. G. Cohen¹, Paul S. Aisen¹, Reisa A. Sperling⁵
¹Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ²UC Irvine - Irvine (United States), ³University of Pennsylvania - Philadelphia (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital - Boston (United States)
- P003** **Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of A β oligomer-targeting ACU193 in early Alzheimer's disease**
Robyn Moxon¹, Todd Feaster¹, Gopalan Sethuraman¹, Alyssa Carroll¹, Siew Tin Gan¹, Shane Ziembra¹, Kimber Price¹, Vladimir Skljarevski¹, Karen Sundell¹, Janice Hitchcock¹, Eric Siemers¹
¹Acumen Pharmaceuticals - Charlottesville (United States)
- P004** **Investigating Treatment Effect Heterogeneity in Data-Driven Subgroups of TOMMORROW**
 Cameron Shand¹, Neil Oxtoby¹
¹University College London - London (United Kingdom)
- P005** **How should the next generation of Alzheimer's Disease clinical trials be analyzed in the estimands framework? The GRADUATE I & II experience**
 Rachid Abbas¹, Nicola Voyle², Giuseppe Palermo¹, Geoff Kerchner¹, Christopher Lane², Angeliki Thanasopoulou¹, Janice Smith², Rachelle Doody^{1,3}, Paul Delmar¹
¹F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Products Ltd - Welwyn Garden City (United Kingdom), ³Genentech, Inc. - South San Francisco (United States)
- P006** **Factors Influencing Older Adults' Intention to Participate in a Secondary Prevention Trial in Alzheimer's Disease**
Emily Largent¹, Joshua Grill², Jason Karlawish¹, Amy Bleakley³
¹University of Pennsylvania - Philadelphia (United States), ²University of California, Irvine - Irvine (United States), ³University of Delaware - Newark (United States)
- P007** **Evaluation of machine learning models that predict Alzheimer's disease progression in observational studies and randomized clinical trials**
Sofia Broomé¹, Shibeshih Belachew², Bastien Caba², Enrica Cavedo¹, Jonathan Dubois², Audrey Gabelle², Refaat Gabr², Arie Gafson², Despoina Ioannidou¹, Xiaotong Jiang², Yan Jin², Neil Oxtoby³, Menglan Pang², Nikos Paragios¹, Willem Huijbers²
¹TheraPanacea - Paris (France), ²Biogen - Cambridge (United States), ³Toybox Science - Mildenhall (United Kingdom)
- P008** **Study Design of POLARIS-AD, AR1001 Phase 3 Study in Early Alzheimer's Disease**
Sharon Sha¹, SangYun Kim^{2,3}, Jeffrey Cummings⁴, Charlotte Teunissen⁵, David Greeley⁶, Monica Kim⁶, James Rock⁶, Fred Kim⁶, Jai Jun Choung⁶
¹Stanford University - Palo Alto (United States), ²Seoul National University College of Medicine - Seoul (Korea, Republic of), ³Seoul National University Bundang Hospital - Seoul (Korea, Republic of), ⁴University of Nevada, Las Vegas - Las Vegas (United States), ⁵Amsterdam University Medical Centers - Amsterdam (Netherlands), ⁶AriBio Co., Ltd - Seongnam (Korea, Republic of)
- P009** **Enrichment for clinical trial of early AD using combination of PHS and plasma p-tau181 as screening instruments**
Xin Wang¹, Xinran Wang¹, Steven Edland¹, Iris Broce¹, Sarah Banks¹
¹University of California, San Diego - La Jolla (United States)
- P010** **Validating an automatic phone-based speech biomarker measuring cognition SB-C against PACC5 and MoCA in the Swedish H70 epidemiological cohort**
 Johannes Tröger¹, Fredrik Öhman², Elisa Mallick¹, Alexandra König¹, Johan Skoog², Anna Zettergren², Silke Kern², Simona Sacuiu², Michael Schöll², Nicklas Linz¹, Ingmar Skoog²
¹Ki elements GmbH - Saarbrücken (Germany), ²Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden)
- P011** **A systematic review and meta-analysis of agitation trials in individuals with dementia: Are cognitive measures needed?**
Heather Belanger¹, Kavita Gohil¹, Jeffrey Finman¹, Gary Kay¹
¹Cognitive Research Corporation (CRC), University of South Florida - St Petersburg (United States)
- P012** **Effects of Informant Replacement in Alzheimer's Disease Clinical Trials**
Mikaela Nishida¹, Michelle Nuno², Joshua Grill¹, Daniel Gillen¹
¹University of California, Irvine - Irvine (United States), ²University of Southern California - Los Angeles (United States)
- P013** **Harnessing the power of continuous time: Learnings from recent large clinical trial data**
Paul Delmar¹, Lars Lau Raket², John O'gorman³, Guoqiao Wang⁴, Michael Donohue⁵
¹F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ²Eli Lilly and Company, Indianapolis, USA - Indianapolis (United States), ³Biogen - Cambridge (United States), ⁴Washington University School of Medicine, - Saint Louis (United States), ⁵University of Southern California - San Diego (United States)
- P014** **Internet-based insomnia intervention to prevent cognitive decline: Use of Internet-based recruitment, intervention, and assessment methods**
Meghan Mattos¹, Carol Manning¹, Wen You¹, Kirsten Macdonnell¹, Lee Ritterband¹
¹University of Virginia - Charlottesville (United States)

POSTER PRESENTATIONS

- P015 Exploring the Impact of Baseline Discordance Between Functional Scales in Early AD Clinical Trials**
Alan Kott¹, Xingmei Wang², [David Miller](#)²
¹Signant Health - Prague (Czech Republic), ²Signant Health - Blue Bell (United States)
- P016 A pragmatic, investigator-driven process for disclosure of amyloid PET scan results to ADNI4 research participants**
[Claire Erickson](#)¹, Jason Karlawish¹, Joshua Grill², Kristin Harkins¹, Susan Landau³, Ronald Petersen⁴, Paul Aisen⁵, Michael Weiner⁶, Emily Largent¹
¹University of Pennsylvania - Philadelphia (United States), ²University of California Irvine - Irvine (United States), ³University of California Berkeley - Berkeley (United States), ⁴Mayo Clinic - Rochester (United States), ⁵University of Southern California - San Diego (United States), ⁶University of California San Francisco - San Francisco (United States)
- P017 RG6289, a new γ -secretase modulator for the treatment of Alzheimer's disease: Dose selection for a phase II trial based on population PK/PD modeling**
Dominik Lott¹, [Agnes Portron](#)¹, Mizan Alam¹, Carina Cantrill¹, Ruth Croney², Fabien Alcaraz³, Rosa Maria Rodríguez Sarmiento⁴, Lothar Lindemann³, Lutz Mueller¹, Thomas Mueggler³, Taner Vardar⁵, Rosanna Tortelli³, Stefan Sturm¹, Irene Gerlach³
¹Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Limited - Welwyn (United Kingdom), ³Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁴Medicinal Chemistry, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁵Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland)
- P018 Recruitment Source, Eligibility, and Reason for Prescreen-Fail across Sex, Race & Ethnicity: A Preliminary Analysis of Prescreening Data from the AHEAD Study**
[Dylan Kirn](#)^{1,2}, Shunran Wang³, Joshua D. Grill⁴, Karin Ernstrom³, Akpewweoghene Ikoba², Emily Sprague¹, Gustavo Jimenez-Maggiora³, Elizabeth Shaffer³, Reisa Sperling^{1,5}, Rema Raman³
¹Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), ³Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁴Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), ⁵Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)
- P019 Impact of recruitment methods on racial and ethnic diversity: results from the Davis Memory and Aging Cohort at Mass General Brigham**
[Stephanie Moreno](#)¹, Akpewweoghene Ikoba¹, Caitlyn Christiano¹, Juliana Aya Ussui Anzai¹, Andrea Roman¹, Dylan Kirn², Lenore Jackson-Pope¹, Martha Cecilia Muniz¹, Jasmeeer P. Chhatwal³, Seth A. Gale⁴, Gad A. Marshall⁴, Reisa A. Sperling⁴, Hyun-Sik Yang⁵, Dennis J. Selkoe⁴, Dorene M. Rentz⁶
¹Center for Alzheimer Research and Treatment, Brigham and Women's Hospital - Boston (United States), ²Department of Neurology, Brigham and Women's Hospital - Boston (United States), ³Department of Neurology, Mass General Hospital - Boston (United States), ⁴Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁵Department of Neurology, Brigham and Women's Hospital - Boston (United States), ⁶Center for Alzheimer Research and Treatment, Brigham and Women's Hospital - Boston (United States)
- P020 Improving Diverse Recruitment in an Early Phase Therapeutic AD trial through a Pre-screening Study, Apeleia-001**
Dawn Batchuluun¹, Katy Smith¹, Tamiko Magee-Rodgers¹, [Leigh Zisko](#)¹, John Dwyer¹, Jason Bork¹, Richard Mohs¹, Julie Schwartzbard², Anthony Bannon³, Shau Yu Lynch³, Christa Lee³, Danielle McGeeney³
¹Global Alzheimer's Platform Foundation - Washington (United States), ²Aventura Hospital and Medical Center - Aventura (United States), ³AbbVie, Inc. - North Chicago (United States)
- P021 On Adaptive Randomization in Time-to-Event Alzheimer's Disease Clinical Trials**
[Navneet Hakhu](#)¹, Joshua Grill¹, Daniel Gillen¹
¹University of California, Irvine - Irvine (United States)
- P022 Views and perceptions of amyloid imaging among racial and ethnic groups in a preclinical Alzheimer's disease trial**
[Christina M. Magana-Ramirez](#)¹, Gimarie Irizarry², Daniel L. Gillen^{1,3}, Joshua D. Grill^{2,3,4}
¹Department of Statistics, University of California, Irvine, California - Irvine (United States), ²Department of Neurobiology and Behavior, University of California, Irvine, California - Irvine (United States), ³Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California - Irvine (United States), ⁴Department of Psychiatry and Human Behavior, University of California, Irvine, California - Irvine (United States)
- P023 Application of the personalized medicine approach to a behavioral intervention study: the Internet-based Conversational Engagement Clinical Trial (I-CONNECT)**
[Chao-Yi Wu](#)¹, Kexin Yu², Steven Arnold¹, Sudeshna Das¹, Hiroko Dodge¹
¹Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), ²Neurology, Oregon Health & Science University - Portland (United States)
- P024 Understanding Non-progressors in Alzheimer's Disease Clinical Trials**
[Shuang Wu](#)¹, Jennifer Murphy¹, Wei Feng², Philip Montenegro¹, Ying Tian¹
¹Biogen - Cambridge (United States), ²Keros Therapeutics - Lexington (United States)
- P025 A Phase 2 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Aducanumab in Subjects with Early Alzheimer's Disease**
[Lloyd Tran](#)¹, Fern Vu¹, Markku Kurkinen¹
¹Biomed Industries, Inc. - San Jose
- P025B A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease**
[Lloyd Tran](#)¹, Fern Vu¹, Markku Kurkinen¹
¹Biomed Industries, Inc. - San Jose (United States)

POSTER PRESENTATIONS

Poster presentations presented **remotely** are indicated with this icon: 

- P026 **Simulating Covariate-Adaptive Randomization Strategies in Alzheimer's Disease Clinical Trials**
Charlene Flournoy¹, Rema Raman¹, Paul Aisen¹, Michael Donohue¹
¹USC Alzheimer's Therapeutic Research Institute - San Diego (United States)
- P027 **Persistence Pays - The Relationship Between Repeated Reschedule Attempts and Eventual Attendance and Screening Rates**
Sarah Starling¹, Gabriela Munoz¹, Paul Sablone¹, Miriam Evans¹, Stephanie Rutrick¹
¹Adams Clinical - Watertown (United States)
- P028 **Methodologies that Support the Identification of Disease Modifying Therapies Which Are a Radical Shift from Short Acting Symptomatic Treatments: Owning Instead of Renting Our Treatment Effects**
Suzanne Hendrix¹, Craig Mallinckrodt¹, Samuel Dickson¹
¹Pentara - Salt Lake City (United States)
- P029 **The time machine: how converting treatment effects to time savings will change the world**
Samuel P. Dickson¹, Benjamin A. Haaland¹, Joshua Christensen¹, Matthew Morgan¹, Craig H. Mallinckrodt¹, Suzanne B. Hendrix¹
¹Pentara Corporation - Salt Lake City (United States)
- P030 **Why your AD clinical trial might succeed (the right reasons and the wrong ones)**
Kent Hendrix¹, Suzanne Hendrix¹, Samuel Dickson¹
¹Pentara - Salt Lake City (United States)
- LP001 **Phase 3 POLARIS-AD: AR1001 study design in early Alzheimer's disease**
Sharon Sha¹, Sangyun Kim², Jeffrey Cummings³, Charlotte Teunissen⁴, David Greeley⁵, James Rock⁵, Matthew Choung⁵
¹Stanford University - Palo Alto (United States), ²Seoul National University College of Medicine - Seoul (Korea, Republic of), ³University of Las Vegas - Las Vegas (United States), ⁴Amsterdam UMC - Amsterdam (Netherlands), ⁵AriBio Co LTD - San Diego (United States)
- LP002 **Negative Amyloid biomarkers Following Treatment (NAFT): a call for harmonization and future investigations**
Claire Sexton¹, Jeffrey Cummings², Douglas Galasko³, Milos Ikonovic⁴, Susan Landau⁵, Jorge Llibre-Guerra⁶, Catherine Mummery⁷, Rik Ossenkoppele^{8,9}, Julie Price¹⁰, Shannon Risacher¹¹, Ruben Smith⁹, Christopher Van Dyck¹², Maria Carrillo¹, Renaud La Joie^{13,14}
¹Alzheimer's Association - Chicago (United States), ²University of Nevada Las Vegas - Las Vegas (United States), ³University of California, San Diego - San Diego (United States), ⁴VA Pittsburgh Healthcare System - Pittsburgh (United States), ⁵University of California, Berkeley - Berkeley (United States), ⁶Washington University School of Medicine in St Louis - St Louis (United States), ⁷University College London - London (United Kingdom), ⁸Amsterdam University Medical Center - Amsterdam (Netherlands), ⁹Lund University - Lund (Sweden), ¹⁰Massachusetts General Hospital - Boston (United States), ¹¹Indiana University School of Medicine - Indianapolis (United States), ¹²Yale School of Medicine - New Haven (United States), ¹³University of California, San Francisco - San Francisco (United States), ¹⁴University of Pittsburgh School of Medicine - Pittsburgh (United States)
- LP003 **Implications of Missing Data and Dropouts in Randomized Clinical Trials in Early Alzheimer's Disease**
Donald Berry¹
¹Berry Consultants - Austin (United States)
- LP004 **Determinants of Individual Differences in the Efficacy of Aerobic Exercise to Improve Brain Health and Reduce Alzheimer's Disease Risk in Older African Americans**
Bernadette Fausto¹, Steven Malin², Paul Duberstein³, Kirk Erickson⁴, Liangyuan Hu⁵, Mark Gluck¹
¹Center for Molecular and Behavioral Neuroscience, Rutgers, The State University of New Jersey-Newark - Newark, New Jersey (United States), ²Department of Kinesiology and Health, Rutgers University - New Brunswick, New Jersey (United States), ³Department of Health Behavior, Society and Policy, Rutgers School of Public Health - Piscataway, New Jersey (United States), ⁴AdventHealth Research Institute - Orlando, Florida (United States), ⁵Department of Biostatistics and Epidemiology, Rutgers School of Public Health - Piscataway, New Jersey (United States)
- LP005 **Investigating partially discordant results in aducanumab ENGAGE and EMERGE trials using Subtype and Stage Inference machine learning**
Neil Oxtoby¹, Cameron Shand¹, Frederik Barkhof^{1,2,3}
¹UCL Centre for Medical Image Computing, Department of Computer Science, University College London - London (United Kingdom), ²UCL Queen Square Institute of Neurology, University College London - London (United Kingdom), ³Department of Radiology & Nuclear Medicine, Amsterdam University Medical Center - Amsterdam (Netherlands)
- LP006 **Confirmatory but not independent? Implications of using early phase results as confirmatory evidence in AD registration trials**
Daniel Gillen¹, Joshua Grill¹, Sarah Schlund¹, Scott Emerson²
¹University of California, Irvine - Irvine (United States), ²University of Washington - Seattle (United States)
- LP007 **Optimizing Alzheimer's Disease Clinical Trial Data for Facilitating Scientific Discovery**
Kathleen A. Welsh-Bohmer¹, Stephen Haneline², Rebecca Wilgus¹, Jack Shostak¹, Haotian Zou³, Sheng Luo¹, Michael Lutz⁴, Brenda Plassman⁴, Daniel K. Burns², Rebecca Li⁵, Frank Rockhold¹, Matthew Clement⁶, Tetsuyuki Maruyama⁶
¹Duke Clinical Research Institute (DCRI) - Durham (United States), ²Zinfandel - Chapel Hill (United States), ³UNC-Chapel Hill - Chapel Hill (United States), ⁴Duke University - Durham (United States), ⁵Vivli - Cambridge (United States), ⁶Alzheimer's Disease Data Initiative (ADDI) - Kirkland (United States)
- LP008 **Incorporating the Study Participant's Voice into Early Development of ACU193 for Early Alzheimer's Disease: A Qualitative Interview Study Following Participation in the INTERCEPT-AD Study**
Kelly Johnston¹, Victoria Brown¹, Carrie Presnall¹, Elizabeth Merikle¹, Stephanie Cline², Todd Feaster²
¹Fortrea, Inc. - Durham (United States), ²Acumen Pharmaceuticals - Charlottesville (United States)

POSTER PRESENTATIONS

- LP009** **Reducing screen failure rates due to biomarker cut-offs in early Alzheimer's disease trials using a prognostic model**
Angela Tam¹, César Laurent¹, Christian Dansereau¹
¹Perceiv AI - Montreal (Canada)
- LP010** **Rationale and design of a Phase 2b trial to evaluate the efficacy of a specific inhibitor of 11β-HSD1, Xanamem®[®], in mild and moderate AD**
Dana Hilt¹, Jack Taylor¹, Tamara Miller¹, John Harrison^{2,3,4}, Christopher Chen⁵, Craig Ritchie²
¹Actinogen Medical - Sydney (Australia), ²Scottish Brain Sciences - Edinburgh (United Kingdom), ³King's College - London (United Kingdom), ⁴Alzheimercenterum, AUMC - Amsterdam (Netherlands), ⁵Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore)
- LP011** **Impact of a Site Supplemental Funding Program to Alleviate Recruitment Burden: Experiences in the Preclinical Alzheimer's Disease AHEAD Study**
Leona K Shum¹, Rema Raman¹, Oliver Langford¹, Victoria Salcedo¹, Andy Liu¹, Reisa Sperling^{2,3}, Joshua D Grill⁴, Crystal M Glover^{5,6,7}, Paul Aisen¹, Keith Johnson^{2,3}, Shobha Dhadha⁸, Michael Irizarry⁸, Doris Molina-Henry¹
¹Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), ²Brigham and Women's Hospital, Harvard Medical School - Boston, Ma (United States), ³Massachusetts General Hospital, Harvard Medical School - Boston, Ma (United States), ⁴University of California, Irvine - Irvine, Ca (United States), ⁵Department of Neurological Sciences, Rush Medical College - Chicago, Il (United States), ⁶Department of Psychiatry and Behavioral Sciences, Rush Medical College - Chicago, Il (United States), ⁷Rush Alzheimer's Disease Center - Chicago, Il (United States), ⁸Eisai Inc. - Nutley, Nj (United States)
- LP012** **Establishing an evidence-based patient recruitment strategy through a site recruitment needs assessment for a hospice-eligible population with dementia**
Karla López Aguiñiga¹, Arianne Zokas Fritts², Jacobo Mintzer², Brigid Reynolds³, Melanie Chadwick³, Olga Brawman-Mintzer⁴, Gregory Jicha⁵, Mark Kindy⁶, Branko Huisa-Garate⁷, Jeffrey Keller⁸, Taylor Clanton¹, Brendon Smith¹, Joshua D. Grill⁹, Paul Aisen¹, Rema Raman¹
¹Alzheimer's Therapeutic Research Institute (ATRI) - San Diego (United States), ²Medical University of South Carolina - Charleston (United States), ³Georgetown University - District Of Columbia (United States), ⁴Ralph H. Johnson Veteran Affairs Medical Center - Charleston (United States), ⁵University of Kentucky - Lexington (United States), ⁶University of South Florida - Tampa (United States), ⁷The Neuron Clinic - San Marcos (United States), ⁸Pennington Biomedical Research Center - Baton Rouge (United States), ⁹University of California, Irvine - San Diego (United States)
-  **LP013** **Inviting Diverse Communities to Clinical Research Participation through Medical Record Retrieval and Review**
 Katie King¹, Erin Beck²
¹Biogen - Wilmington (United States minor outlying islands), ²SiteRx - New York (United States minor outlying islands)
-  **LP014** **Addressing Representative Alzheimer's Disease Enrollment in Clinical Research via Real-World Conversion Analysis across the Recruitment Funnel**
Michael Stalder¹
¹SiteRx - New York (United States)
-  **LP015** **Examining the role of community engagement in enhancing the participation of minoritized communities in Alzheimer's disease clinical trials; a rapid review**
Sanaz Dabiri¹, Doris Molina-Henry¹
¹Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)
-  **LP016** **Developing a Screening Platform for Early-Phase Clinical Trials to Prevent AD (The EPICH Platform)**
Gene Bowman¹, Hira Shrestha¹, Hiroko Dodge², Jody-Lynn Lupo³, Jeremiah Momper⁴, James Silverman³, Carolyn Revta³, Kevin Ryneerson⁵, Steven Edland⁵, Jonathan Rosand⁶, Steven Arnold², Howard Feldman⁷, Rudolph Tanzi¹
¹McCance Center for Brain Health, Clinical Trials Unit and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), ²Interdisciplinary Brain Center, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), ³Alzheimer's Disease Cooperative Study, University of California San Diego - San Diego (United States), ⁴Department of Pharmacology, University of California San Diego - San Diego (United States), ⁵Department of Neurosciences, University of California San Diego - San Diego (United States), ⁶McCance Center for Brain Health, Clinical Trials Unit, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - San Diego (United States), ⁷Alzheimer's Disease Cooperative Study and Department of Neurosciences, University of California San Diego - San Diego (United States)

THEME: Clinical Trials: Results

-  **P031** **Combined exercise and cognitive interventions for adults with mild cognitive impairment and dementia: A systematic review and network meta-analysis**
Dandan Xue¹, Polly W.c. Li¹, Doris S.f. Yu¹, Rose S.y. Lin², Yuewen Lao³
¹School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong - Hong Kong (Hong Kong), ²University of Rochester School of Nursing, New York, USA - New York (United States), ³Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Hangzhou (China)
- P032** **Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Eileen Priest¹, Corissa Lau¹, Hazel White¹, Michael Irizarry², Klaus Romero¹, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai Inc. - Nutley (United States)

- P033 **Critical Path for Alzheimer's Disease (CPAD) Consortium: Data-Driven Solutions for Clinical Trial Design and Informed Decision Making**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Corissa Lau¹, Eileen Priest¹, Hazel White¹, Michael Irizarry², Gregory Klein³, Klaus Romero¹, Antoine Leuzy^{1,4,5}, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai Inc. - Nutley (United States), ³F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁴Lund University - Malmö (Sweden), ⁵Enigma Biomedical USA - Knoxville (United States)
- P034 **Combination Treatment of a Novel β 2 Adrenoceptor Agonist, CST-2032, and Nadolol Improves Cognitive. Measures in Patients with Alzheimer's Disease**
John Harrison¹, Renee Martin², Peter Butera², Judy Reynolds², Anthony Ford², Gabriel Vargas²
¹Institute of Psychiatry, Psychology & Neuroscience King's College London - London (United Kingdom), ²CuraSen Therapeutics - San Carlos (United States)
- P035 **Safety and Feasibility Trial of Dapagliflozin in Early Alzheimer's Disease**
Jeffrey Burns¹, Jill Morris¹, Eric Vidoni¹, Heather Wilkins¹, In-Young Choi¹, Phil Lee¹, Suzanne Hunt¹, Jonathan Mahnken¹, William Brooks¹, Rebecca Lepping¹, Peter Adany¹, Aditi Gupta¹, Russell Swerdlow¹
¹University Of Kansas Alzheimer's Disease Center - Kansas City (United States)
- P036 **Phase 3 Clinical Studies in Alzheimer's and Parkinson's disease; Interim Analysis and FDA guidance for both indications**
Cheng Fang¹, Eve Damiano¹, Melissa Gaines¹, Michele Shaffer², Anne-Marie Nagy³, Laurie Sanders⁴, Maria Maccacchini¹
¹Annovis Bio - Berwyn (United States), ²Wuxi - Austin (United States), ³TFS - Lund (Sweden), ⁴DCRI - Durham (United States)
-  P037 **Safety, tolerability, and pharmacokinetics findings in a Phase 1 single dose study of donanemab in healthy Chinese participants**
 Yimin Cui¹, Rihan Wu², Ivelina Gueorguieva³, Chenxi Qian², Junyu Xu¹
¹Peking University First Hospital - Beijing (China), ²Eli Lilly and Company - Shanghai (China), ³Eli Lilly and Company - Bracknell (United Kingdom)
- P038 **Safety of higher doses of gantenerumab in the open-label extension of the dominantly inherited Alzheimer's Network trials unit (DIAN-TU-001 trial)**
Jorge Llibre-Guerra¹, Nelly Joseph-Mathurin¹, Yan Li¹, Guoqiao Wang¹, Andrew Aschenbrenner¹, Xiong Chengjie¹, Brian Gordon¹, Janice Hitchcock², Richard Perrin¹, Carsten Hofmann³, Jakub Wojtowicz⁴, Atri Alireza⁵, Eric Mcdade¹, Randall Bateman¹, David Clifford¹
¹Washington University School Of Medicine In St.louis - St. Louis (United States), ²Hitchcock Regulatory Consulting, Inc - St. Louis (United States), ³Roche Innovation Center Basel - Basel (Switzerland), ⁴F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁵Banner Sun Health Research Institute - Sun, Arizona (United States)
- P039 **A Single Ascending Dose Study of ABBV-916, an Anti-Amyloid Antibody, in Healthy Volunteers**
Sagar Bachhav¹, Hana Florian², Joey Boiser³, Yamin Wang⁴, Dee-Dee Shiller¹, Shau Yu Lynch², Ole Graff², Hao Xiong¹
¹Clinical Pharmacology, AbbVie Inc - North Chicago (United States), ²Neuroscience Clinical Development, AbbVie Inc - North Chicago (United States), ³Pharmacovigilance and Patient Safety, AbbVie Inc - North Chicago (United States), ⁴Statistics, AbbVie Inc - North Chicago (United States)
-  P040 **Efficacy of anti-amyloid- β monoclonal antibody therapy in prodromal versus mild dementia due to Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials**
 Julyana Dantas¹, Pedro Romeiro², Caroline Dagostin³, Nicole Felix⁴, Denilsa Navalha⁵, Antonio Mutarelli⁶, Paulo Caramelli⁷, Sávio Batista⁸, Larissa Teixeira⁹
¹Federal University of Rio Grande do Norte - Natal (Brazil), ²University Center Tiradentes - Maceió (Brazil), ³University of the Extreme South of Santa Catarina - Criciúma (Brazil), ⁴Federal University of Campina Grande - Campina Grande (Brazil), ⁵Eduardo Mondlane University - Maputo (Mozambique), ⁶Federal University of Minas Gerais - Belo Horizonte (Brazil), ⁷Behavioral and Cognitive Neurology Unit, Federal University of Minas Gerais - Belo Horizonte (Brazil), ⁸Universidade Federal do Rio de Janeiro, - Rio de Janeiro (Brazil), ⁹Universidade Federal de Campina Grande - Campina Grande (Brazil)
- P041 **High adherence and tolerability of a sensory stimulation system in a 6-month sham-controlled clinical trial in Alzheimer's disease**
Chandran V Seshagiri¹, Zach Malchano¹, Alyssa Boasso¹, Mihály Hajós¹, Evan Hempel¹, Kahlil G Saikali¹, Brent Vaughan¹, Ralph Kern¹
¹Cognito Therapeutics - Cambridge (United States)
- P043 **Effect of ALZ-801 (Valiltramiprosate), an Oral Inhibitor of Amyloid Oligomer Formation, on Plasma Biomarkers, Volumetric Brain Imaging Biomarkers, and Clinical Outcomes of Alzheimer's Disease: 12-Month Results of Phase 2 Biomarker Study in Early AD APOE4 Carrier Subjects**
John Hey¹, Susan Abushakra¹, Philip Scheltens², Jakub Hort³, Katerina Sheardova^{4,5}, Ladislav Pazdera⁶, Niels Prins⁷, Sterre Rutgers⁷, Paul Dautzenberg⁷, Jeremy Yu¹, Patrick Kessler¹, Luc Bracoud⁸, Aidan Power¹, Joyce Suhy⁸, Martin Tolar¹
¹Alzheon - Framingham (United States), ²Amsterdam University Medical Centers, Alzheimer Center - Amsterdam (Netherlands), ³Charles University Department of Neurology - Brno (Czech Republic), ⁴Memory Center, St. Anne University Hospital - Brno (Czech Republic), ⁵International Clinical Research Center - Brno (Czech Republic), ⁶Vestra Research Clinics - Rychnov And Kněžnou (Czech Republic), ⁷Brain Research Center - Den Bosch (Netherlands), ⁸Clario, Inc. - San Mateo (United States)
- P044 **Safety and pharmacokinetics of multiple ascending doses of E2511, a novel TrkA allosteric modulator, in healthy volunteers**
Natasha Penner¹, Nancy Hall¹, Cuiyuan Cai², Masaki Mikamoto², Jagadeesh Aluri¹, Takuya Yagi¹, Julia Chang¹, Ali Ardati¹, Steve Hersch¹, Luigi Giorgi³, Larisa Reyderman¹
¹Eisai - Nutley (United States), ²Eisai - Tsukuba (Japan), ³Eisai - Hatfield (United Kingdom)

POSTER PRESENTATIONS

- P045** **ARIA by Clinical Subgroup and Baseline Amyloid PET Centiloid Levels from the Lecanemab Clarity AD Study**
Marwan Sabbagh¹, David Li², Shobha Dhadda², Michael Irizarry², Steve Hersch², Luigi Giorgi², Andre Matta³, Lynn Kramer²
¹Barrow Neurological Institute - Phoenix (United States), ²Eisai Inc - Nutley (United States), ³Eisai Co., Inc - Hatfield (United Kingdom)
- LP017** **A Phase 1b Double Blind Multiple Ascending Dose Study of the Safety and Pharmacokinetics of NTRX-07 in Normal Volunteers and Patients with Mild Cognitive Impairment or Early Alzheimer's Disease**
Joseph Foss¹, Tony Giordano¹, Mariana Kiraly¹
¹NeuroTherapia, Inc. - Cleveland (United States)
- LP018** **Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer's disease**
Philip Scheltens¹, Alireza Atri^{2,3,4}, Howard H. Feldman⁵, Oskar Hansson^{6,7}, Filip K. Knop^{8,9,10,11}, Mary Sano^{12,13}, Claus Dethlefsen¹⁴, Peter Johannsen¹⁴, Teresa León Colombo¹⁵, Charlotte T. Hansen¹⁴, Jeffrey Cummings¹⁶
¹Alzheimer Centre, VU University Medical Center Amsterdam - Amsterdam (Netherlands), ²Banner Sun Health Research Institute - Sun City, Az (United States), ³Banner Alzheimer's Institute - Phoenix, Az (United States), ⁴Brigham and Women's Hospital, Harvard Medical School - Boston, Ma (United States), ⁵Alzheimer's Disease Cooperative Study, Department of Neurosciences University of California San Diego - La Jolla, Ca (United States), ⁶Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), ⁷Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁸Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen - Hellerup (Denmark), ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), ¹⁰Steno Diabetes Center Copenhagen - Herlev (Denmark), ¹¹Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), ¹²Kahn School of Medicine at Mount Sinai - New York, Ny (United States), ¹³James J Peters VAMC - Bronx Ny (United States), ¹⁴Novo Nordisk A/S - Søborg (Denmark), ¹⁵Novo Nordisk A/S - Madrid (Spain), ¹⁶University of Nevada - Las Vegas, Nv (United States)
- LP019** **The Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE) Study**
Carol Van Hulle¹, Hanna Zylstra¹, Kate Cronin¹, Aleshia Cole¹, Elena Beckman¹, Allison Eierman², Madeleine Blazel³, Karen Lazar¹, Kevin Johnson¹, Leonardo Rivera¹, Carey Gleason¹, Henrik Zetterberg⁴, Sterling Johnson¹, Cynthia Carlsson¹
¹University of Wisconsin-Madison - Madison (United States), ²Medical College of Wisconsin-Green Bay - Green Bay (United States), ³Case Western Reserve University School of Medicine - Cleveland Ohio (United States), ⁴Sahlgrenska Academy - Malmö (Sweden)
- LP020** **Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease and Major Depressive Disorder**
Lloyd Tran¹, Zung Tran¹
¹Biomed Industries, Inc. - San Jose (United States)
- LP022** **RetiSpec's AI-based retinal test: Results of a multi-site, prospective, validation study to predict brain A β pathology in a diverse population of adults with Preclinical, MCI, and Probable Alzheimer's disease**
Alon Hazan¹, Catherine Bornbaum¹, Eliav Shaked¹, Jennifer Giordano¹, Yochai Edlitz^{2,3}, David He⁴, Diana Kerwin⁵
¹RetiSpec - Toronto (Canada), ²Weizmann Institute of Science - Rehovot (Israel), ³MILAIA Data Science - Tel Aviv (Israel), ⁴Analytical Solutions Group, Inc. - North Pontomac (United States), ⁵Kerwin Medical Center - Dallas (United States)
- LP023** **Dopaminergic Therapy for Frontotemporal Dementia Patients: preliminary results from a phase 2 multi-site, Randomized Clinical Trial**
Martina Assogna^{1,2}, Francesco Di Lorenzo¹, Sonia Bonni¹, ALPerto Benussi³, Ilaria Borghi¹, Emanuele Cerulli Irelli⁴, Enrico Premi³, Valentina Cantoni³, Valentina Pezzopane¹, Lucia Mencarelli¹, Caterina Motta², Clarissa Ferrari⁵, Martorana Alessandro², Giacomo Koch^{1,6}
¹Department of Clinical and Behavioural Neurology, Santa Lucia Foundation - Rome (Italy), ²Memory Clinic, Department of Systems Medicine, University of Tor Vergata, - Rome (Italy), ³Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, - Brescia (Italy), ⁴Department of Human Neurosciences, Sapienza, University of Rome - Rome (Italy), ⁵Office of Research and Clinical Trials, Fondazione Poliambulanza Istituto Ospedaliero, - Brescia (Italy), ⁶Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), - Ferrara (Italy)
- LP024** **RESULTS FROM: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimer's Disease**
Willem De Haan^{1,2}, Anthony Caggiano³, Philip Scheltens⁴, Michael Grundman⁵, Eliz Scheijbeler^{1,2}, Mary Hamby³, Everard Vijverberg¹
¹Department of Clinical Neurophysiology and MEG Center, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ²Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ³Cognition Therapeutics - Purchase (United States), ⁴EQT Group - Amsterdam (Netherlands), ⁵Global R&D Partners and Department of Neurosciences, University of California - San Diego (United States)
- LP025** **Palmitoylethanolamide Combined with Luteoline in Frontotemporal Dementia patients (PEA-FTD): A phase 2 Randomized Clinical Trial**
Martina Assogna¹, Francesco Di Lorenzo¹, Sonia Bonni¹, Ilaria Borghi¹, Emanuele Cerulli Irelli², Lucia Mencarelli¹, Michele Maiella¹, Elias Paolo Casula¹, Valentina Pezzopane¹, Caterina Motta³, Clarissa Ferrari⁴, Carlo Caltagirone¹, Martorana Alessandro⁵, Giacomo Koch^{1,6}
¹Department of Clinical and Behavioural Neurology, Santa Lucia Foundation - Rome (Italy), ²Department of Human Neurosciences, Sapienza, University of Rome - Rome (Italy), ³Memory Clinic, University of Tor Vergata, - Rome (Italy), ⁴Office of Research and Clinical Trials, Fondazione Poliambulanza Istituto Ospedaliero, - Brescia (Italy), ⁵Memory Clinic, Department of Systems Medicine, University of Tor Vergata - Rome (Italy), ⁶Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), - Ferrara (Italy)

- LP026 OVERTURE Open-Label Extension Data Confirms Safety, Adherence and Durability of Treatment Benefits over 18 Months**
Ralph Kern¹, Colin Kuang¹, Mihaly Hajos¹, Alex Konisky¹, Alyssa Boasso¹, Evan Hempel¹, Brent Vaughan¹, Chandran Seshagiri¹, Zach Malchano¹, Suzanne Hendrix², Khalil Saikali¹
¹Cognito Therapeutics - Cambridge (United States), ²Pentara Corporation - Salt Lake City (United States)
- LP027 Baseline risk factors for ARIA-E in the GRADUATE I and II studies of gantenerumab**
Paul Delmar¹, Nicola Voyle², Michael Grundman³, Stephen Salloway⁴, Jakub Wojtowicz¹, Marco Lyons², Christopher Lane², Angeliki Thanasopoulou¹, Simona Rossomanno¹, Szofia Bullain¹, Gregory Klein¹, Tobias Bittner⁵, Andres Schneider¹, Janice Smith², Rachele Doody⁵
¹F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Products Ltd - Welwyn Garden City (United Kingdom), ³Global R&D Partners, LLC and Dept. of Neurosciences, University of California - San Diego (United States), ⁴Butler Hospital and Warren Alpert Medical School of Brown University - Providence (United States), ⁵F. Hoffmann-La Roche Ltd and Genentech, Inc. - Basel (Switzerland)
- LP028 Donanemab: Characterization of immunogenicity from the TRAILBLAZER-ALZ & TRAILBLAZER-ALZ 2 trials**
Garrett Mullins¹, Paul Ardayfio¹, Ivelina Gueorguieva¹, Greg Anglin¹, Jason Bailey¹, Laiyi Chua¹, Jennifer Zimmer¹, Cynthia Evans¹, Emel Nery¹, Hong Wang¹, Rashna Khanna¹, Dawn Brooks¹, John Sims¹
¹Eli Lilly and Company - Indianapolis (United States)
- LP029 Donanemab: Characterizing infusion-related reactions from TRAILBLAZER-ALZ & TRAILBLAZER-ALZ 2**
Paul Ardayfio¹, Garrett Mullins¹, Jennifer Zimmer¹, Cynthia Evans¹, Greg Anglin¹, Ivelina Gueorguieva¹, Emel Nery¹, Hong Wang¹, Rashna Khanna¹, Dawn Brooks¹, John Sims¹
¹Eli Lilly and Company - Indianapolis (United States)
- LP030 Cerebral Amyloid Angiopathy and Comorbid Cardiovascular Risk Factors in APOE4/4 Homozygotes with Early Alzheimer's Disease: Baseline Results from APOLLOE4 Phase 3 Trial of Oral Anti-Amyloid Agent ALZ-801**
Rosalind McInaine¹, Earvin Liang¹, Susan Abushakra¹, David Watson², Merce Boada³, Sharon Cohen⁴, Marwan Sabbagh⁵, Aidan Power¹, Susan Flint¹, Winnie Pak¹, John Hey¹, Martin Tolar¹
¹Alzheon, Inc. - Framingham (United States), ²Alzheimer's Research and Treatment Center - Wellington (United States), ³Ace Alzheimer's Center - Barcelona (Spain), ⁴Toronto Memory Program - Toronto (Canada), ⁵Barrow Neurological Institute - Phoenix (United States)
- LP031 ACI-35.030 anti-phospho-Tau active immunotherapy for the treatment of early Alzheimer's Disease (AD): Update from the Phase 1b/2a study data and perspectives.**
Olivier Sol¹, Johannes Streffer², Julien Mermoud¹, Marija Vukicevic¹, Eva Gollwitzer¹, David Hickman¹, Valérie Hliva¹, Julian Gray¹, Lennert Steukers³, Lingjue Li⁴, Andrea Pfeifer¹, Marie Kosco-VilPois¹, Philip Scheltens⁵
¹AC Immune SA - Lausanne (Switzerland), ²University of Antwerp - Antwerp (Belgium), ³Janssen - Beerse (Belgium), ⁴Janssen - New Jersey (United States), ⁵Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, VUmc - Amsterdam (Netherlands)
-  **LP033 ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay of Target Engagement for the sAβO-Selective Antibody ACU193 in INTERCEPT-AD**
Erika Cline¹, Jerome Moore¹, Hao Zhang¹, Gopalan Sethuraman¹, Eric Siemers¹, Robert Dean¹, Jasna Jerecic¹
¹Acumen Pharmaceuticals - Charlottesville (United States)
-  **LP034 INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer's disease**
Hao Zhang¹, Jerome Moore^{1,2}, Erika Cline¹, Mahsan Rafizadeh¹, Eric Siemers¹, Robert Dean^{1,3}, Jasna Jerecic¹
¹Acumen Pharmaceuticals - Charlottesville (United States), ²Pacific BioDevelopment - Davis (United States), ³Department of Pathology & Laboratory Medicine, Indiana University School of Medicine - Indianapolis (United States)

THEME: Clinical Trials: Imaging

- P046 Brain structure-allelic associations and networks in Alzheimer's disease**
Seokwoo Moon¹
¹Konkuk University Chungju Hospital - Chungju (Korea, Republic of)
- P047 Impact of anodal transcranial direct current stimulation on white matter microstructure integrity in mild cognitive impairment patients according to effect modifiers as risk factors for Alzheimer's disease**
Dong Woo Kang¹
¹Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)

POSTER PRESENTATIONS

- P048 Measuring changes in longitudinal Tau-PET with [18F]MK-6240: group-level vs individualized ROIs definition**
Nick Sidorenko¹, Matteo Tonietto¹, Antoine Leuzy², Gregory Klein¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Malmö (Sweden)
- P049 Regional A β -tau interactions can predict individual-level time periods of the optimal therapeutic window for amyloid-lowering treatments**
Gilhwan Lim¹, Hanna Cho², Chul Hyounng Lyoo², Joon-Kyung Seong^{1,3,4,5}, Wha Jin Lee¹, ADNI: Alzheimer's Disease Neuroimaging Initiative⁶
¹NeuroXT - Seoul (Korea, Republic of), ²Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ³School of Biomedical Engineering, Korea University - Seoul (Korea, Republic of), ⁴Department of Artificial Intelligence, Korea University - Seoul (Korea, Republic of), ⁵Interdisciplinary Program in Precision Public Health, Korea University - Seoul (Korea, Republic of), ⁶Alzheimer's Disease Neuroimaging Initiative - Los Angeles (United States)
- P050 Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome**
Isabel Barroeta¹, Jordi Pegueroles¹, Victor Montal¹, Mateus Rozalem¹, Alejandra Morcillo¹, Sara Zsadanyi¹, Lidia Vaque¹, Bessy Benejam¹, Laura Videla¹, Maria Carmona-Iraqui¹, Alexandre Bejanin¹, Valle Camacho², Albert Flotats², Alberto Lleo¹, Juan Fortea¹
¹Unidad de Memoria, Servicio de Neurología, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona, Barcelona - Barcelona (Spain), ²Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain - Barcelona (Spain)
- P051 Automated brain MRI segmentation using a novel AI-based method**
Thomas Cajgfinger¹, Joël Schaerer¹, Po-Han Chen², Chris Conklin³, Madhura Ingalhalikar³, David Scott⁴, Joyce Suh⁴, Luc Bracoud¹
¹Clario - Lyon (France), ²Clario - Estenfeld (Germany), ³Clario - Philadelphia (United States), ⁴Clario - San Mateo (United States)
- P052 Assessing the Relationship Between Central Cholinergic Integrity and Amyloid Accumulation in Individuals with Down Syndrome Using [18F]-FE0BV and [11C]-PiB PET: Preliminary Data**
Jason K. Russell¹, Alexander C. Conley¹, Brian D. Boyd¹, Rachel Schlossberg¹, Adam J. Rosenberg², Lealani Mae Y. Acosta¹, Michael S. Rafii³, Sepideh Shokouhi¹, Paul A. Newhouse^{1,4}
¹Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), ²Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center - Nashville (United States), ³Alzheimer's Therapeutic Research Institute and Department of Neurology, Keck School of Medicine, University of Southern California - San Diego (United States), ⁴Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System - Nashville (United States)
- P053 Minimizing sample sizes for trials using MK-6240: impact of reference and target tissues**
John Becker¹, Cristina Lois¹, Emma Thibault¹, Grace Del Carmen Montenegro¹, Justin Sanchez², Brian Healy³, Fang Fu¹, Julie Price¹, Georges El Fakhri¹, Keith Johnson¹
¹Massachusetts General Hospital - Boston (United States), ²Washington University School of Medicine - St. Louis (United States), ³Harvard T.H. Chan School of Public Health - Boston (United States)
- P054 Cerebral Amyloid Angiopathy in APOE4/4 Homozygotes with Alzheimer's Disease: Baseline Characteristics of Subjects Enrolled in APOLLOE4 Phase 3 Trial of Oral ALZ-801 in Early AD**
Rosalind McClaine¹, Susan Abushakra¹, Earvin Liang¹, Jerome Barakos², Aidan Power¹, David Watson³, Emer Macsweeney⁴, Anton Porsteinsson⁵, Joyce Suh⁶, John Hey¹, Martin Tolar¹
¹Alzheon, Inc. - Framingham (United States), ²California Pacific Medical Center & Clario - San Francisco (United States), ³Alzheimer's Research and Treatment Center - Wellington (United States), ⁴Re:Cognition Health - London (United Kingdom), ⁵University of Rochester School of Medicine and Dentistry - Rochester (United States), ⁶Clario - San Mateo (United States)
- P055 Changes in cortical microstructure in brain regions associated with cognitive status and disease duration after short-term treatment with XPro1595 for Alzheimer's disease**
Parris Pope¹, Christopher Barnum¹, Raymond Tesi¹, Tom Soeder²
¹INmune Bio, Inc. - Boca Raton (United States), ²Allucent - Cary (United States)
- P056 Association of cholinergic integrity to age, amyloid, cortical volume and cognitive performance in healthy postmenopausal women using [18F]-FE0BV PET**
Alexander Conley¹, Jason Russell¹, Brian Boyd¹, Tonnar Castellano¹, Adam Rosenberg², Brittany Bosko¹, Julie Dumas³, Paul Newhouse^{1,4}
¹Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), ²Department of Radiology, Vanderbilt University Medical Center - Nashville (United States), ³Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont Larner College of Medicine - Burlington (United States), ⁴Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System - Nashville (United States)
- P057 Real-world implementation of patient stratification with faster cognitive decline using MRI-based prediction of regional tau positivity**
Yeong-Hun Song¹, Wha Jin Lee², Joon-Kyung Seong¹
¹Korea University - Seoul (Korea, Republic of), ²NeuroXT - Seoul (Korea, Republic of)

- P058 Association of amyloid PET burden with longitudinal cognitive decline in a heterogeneous Alzheimer's disease research cohort**
Emily Johns¹, Kyan Younes¹, Shubhabrata Mukherjee², Christina B. Young¹, Jesse Mez³, Timothy J. Hohman⁴, Duygu Tosun⁵, Sarah Biber⁶, Walter A. Kukull⁶, Paul Crane², Elizabeth C. Mormino¹
¹Department of Neurology and Neurological Sciences, Stanford University - Palo Alto (United States), ²Department of Medicine, The University of Washington - Seattle (United States), ³Department of Neurology, Boston University - Boston (United States), ⁴Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center - Nashville (United States), ⁵Department of Radiology and Biomedical Imaging, University of California, San Francisco - San Francisco (United States), ⁶Department of Epidemiology, National Alzheimer's Coordinating Center, University of Washington - Seattle (United States)
- P059 Stress-Testing the Centiloid Concept: Validation of the Between-Tracer Accuracy of the Centiloid Method in an Independent Cohort**
Juan Domingo Gispert^{1,2,3}, David Vázquez García⁴, Lyduine.e Collij⁴, Mahnaz Shekari^{1,2,5}, Lucca Presotto^{6,7}, Richard Manber⁷, Robin Wolz^{7,8}, Henrik Zetterberg^{9,10,11,12}, Kaj Blennow^{13,14}, Andrew Stephens¹⁵, Gill Farrar¹⁶, Pieter-Jelle Visser^{17,18,19}, Craig Ritchie²⁰, Frederik Barkhof^{4,21}
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation. Barcelona, Spain - Barcelona (Spain), ²IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain - Barcelona (Spain), ³Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spain - Barcelona (Spain), ⁴Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117, Amsterdam, Netherlands & - Amsterdam (Netherlands), ⁵Universitat Pompeu Fabra, Barcelona, Spain - Barcelona (Spain), ⁶University of Milano-Bicocca - Milan (Italy), ⁷IXICO, London, UK - London (United Kingdom), ⁸Imperial College, London, UK - London (United Kingdom), ⁹Dementia Research Institute, University College London, London, UK - London (United Kingdom), ¹⁰Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK - London (United Kingdom), ¹¹Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China. - Hong Kong (China), ¹²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. - Gothenburg (Sweden), ¹³Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. - Gothenburg (Sweden), ¹⁴Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. - Mölndal (Sweden), ¹⁵Life Molecular Imaging GmbH, Berlin, Germany - Berlin (Germany), ¹⁶GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), ¹⁷Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, Netherlands. - Maastricht (Netherlands), ¹⁸Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam University Medical Center, VU Medical Center, Amsterdam, Netherlands. - Amsterdam (Netherlands), ¹⁹Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden. - Stockholm (Sweden), ²⁰Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. - Edinburgh (United Kingdom), ²¹Institute of Neurology and Centre for Medical Image Computing, University College London, UK - London (United Kingdom)
- P060 Estimating the time between Amyloid- and tau-PET positivity: Implications for Alzheimer's Disease Prevention trials**
Alexis Moscoso¹, Fiona Heeman¹, Tora Dunås¹, Michael Schöll¹
¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden)
- P061 A Novel Tau Staging Scheme Using [18F]MK-6240 PET Visual Read Extent Scores**
Eddie Stage¹, Dustin Wooten¹, John Seibyl², Nicholas Seneca¹, Anthony Bannon¹, Hana Florian¹, Robert Comley¹, Qi Guo¹
¹AbbVie - North Chicago (United States), ²Institute for Neurodegenerative Disorders - New Haven (United States)
- P062 Cortical microstructural changes associated with RBANS scores in cognitively unimpaired and MCI in the European Prevention of Alzheimer's Dementia (EPAD) study**
Mario Torso¹, Ged Ridgway¹, Michele Valotti¹, Ian Hardingham¹, Steven Chance^{1,2}
¹Oxford Brain Diagnostics - Oxford (United Kingdom), ²for the European Prevention of Alzheimer's Dementia (EPAD) Consortium
- P063 Amyloid PET Scan Reads in IDEAS – Comparison of Local Clinician and Expert Reads**
Charles Windon¹, Barry Siegel², Maria Carrillo³, Constantine Gatsonis⁴, Lucy Hanna⁵, Bruce Hillner⁶, Andrew March⁷, Rachel Whitmer⁸, Anupa Arora⁹, Santiago Bullich¹⁰, Christopher Buckley¹¹, Paul Sherwin¹¹, Gil Rabinovici¹
¹Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), ²Mallinckrodt Institute of Radiology, Washington University in St Louis - St. Louis (United States), ³Alzheimer's Association - Chicago (United States), ⁴Department of Epidemiology and Biostatistics, Brown University School of Public Health - Providence (United States), ⁵Center for Statistical Sciences, Brown University School of Public Health - Providence (United States), ⁶Department of Medicine, Virginia Commonwealth University - Richmond (United States), ⁷American College of Radiology - Reston (United States), ⁸Department of Public Health Sciences, University of California, Davis - Davis (United States), ⁹Avid Radiopharmaceuticals - Philadelphia (United States), ¹⁰Life Molecular Imaging GmbH - Berlin (Germany), ¹¹GEHC - Massachusetts (United States)
- LP035 Baseline Regional Flortaucipir Profiles in Preclinical Alzheimer's Disease**
Vikas Kotari¹, Michael Case¹, Karen Holdridge¹, Roy Yaari¹, Aaron Schultz², Keith Johnson³, Paul Aisen⁴, Reisa Sperling², John Sims¹, Sergey Shcherbinin¹
¹Eli Lilly and Company - Indianapolis (United States), ²Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ⁴Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States)
- LP036 Interim MRI safety analysis from a 76-week Phase 3 clinical trial of simufilam in Alzheimer's Disease**
James Kupiec¹, Luc Bracoud², Joyce Suh³, Laura Rodriguez¹, Lindsay Burns¹
¹Cassava Sciences - Austin (United States), ²Clario - Lyon (France), ³Clario - San Mateo (United States)
- LP037 Advancing Practicality for the Real-World Anti-Amyloid Treatment: Application of Solitaire T2-Fluid-Attenuated Inversion Recovery-Based Brain Volumetric Analysis Model**
Hye Weon Kim¹, Zunhyan Rieu¹, Hyunji Lee¹, Min-Woo Lee¹, Jimin Kang², Won-Jin Moon³
¹Research Institute, Neurophat Inc. - Seoul (Korea, Republic of), ²Research Institute of Medical Science, Konkuk University of Medicine - Seoul (Korea, Republic of), ³Department of Radiology, Konkuk University Medical Center - Seoul (Korea, Republic of)

POSTER PRESENTATIONS

- LP038** Longitudinal Tau PET analysis pipeline with consistent progression measures across tracers and diagnoses in commonly used as well as subject-specific AD Regions of Interest
Ziad Saad¹, David Henley^{2,3}, Ritobrato Datta¹, Christopher Rowe⁴, Hartmuth KoLP¹
¹Neuroscience Biomarkers and Global Imaging, Janssen R&D, Johnson & Johnson - San Diego (United States), ²Neuroscience Clinical Development, Janssen R&D, Johnson & Johnson - San Diego (United States), ³Indiana University School of Medicine, ⁴Austin Health and University of Melbourne - San Diego (United States)
- LP039** The utility of [18F]FDG brain uptake to predict disease progression and estimations of sample and effect size compared to clinical scales to help guide clinical trial development plans
Nicholas Seneca¹, Eddie Stage¹, Sjoerd Finnema¹, Scott Gladstein¹
¹Abbvie - North Chicago (United States)
-  **LP040** Stress Testing the CL concept: Validation of Generalizable Centiloid Cut-off Values in Two Large, Independent and Representative Clinical Alzheimer Cohorts
Juan Domingo Gispert^{1,2,3}, Christopher Buckley⁴, Santiago Bullich⁵, Daniele Altomare⁶, Mahnaz Shekari^{7,2,3}, Lyduine Collij^{8,9}, David Vázquez-García⁸, Andrew Stephens⁵, Gill Farrar⁴, Andrew March¹⁰, Renaud La Joie¹¹, Gil Rabinovici¹¹, Giovanni Frisoni⁶, Frederik Barkhof⁸
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation. Barcelona, Spain - Barcelona (Spain), ²IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), ³Universitat Pompeu Fabra - Barcelona (Spain), ⁴GE Healthcare Pharmaceutical Diagnostics - Amersham (United Kingdom), ⁵Life Molecular Imaging GmbH - Berlin (Germany), ⁶Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva - Geneva (Switzerland), ⁷Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva - Barcelona (Spain), ⁸Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 - Amsterdam (Netherlands), ⁹Clinical Memory Research, Lund University - Lund (Sweden), ¹⁰American College of Radiology - Washington (United States), ¹¹Department of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco - San Francisco (United States)
-  **LP041** Improved Differential Diagnosis of Hydrocephalus Ex Vacuo and Idiopathic Normal Pressure Hydrocephalus by Integrating Radscale and Dilatation of Perihippocampal Fissure
Jung-In Lim¹, Soyeong Lee¹, Minkyung Kim², Sun-Won Park³, Jun-Young Lee¹, Jung-Hyo Rhim², Jee-Young Lee⁴, Yu Kyeong Kim⁵, Sang-Hyung Lee⁶
¹Department of Psychiatry, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), ²Seoul National University College of Medicine - Seoul (Korea, Republic of), ³Department of Radiology, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), ⁴Department of Neurology, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), ⁵Department of Nuclear Medicine, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), ⁶Department of Neurosurgery, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of)
-  **LP042** Characterization of distortion correction on DTI measurements in a large multi-center clinical trial
Chris Conklin¹, Stefan Radonjic¹, Luc Bracoud¹, Madhura Ingalkhalikar¹, Saima Rathore², Diana Otero Svaldi², Adam Fleisher², Dave Scott¹
¹Clario - Philadelphia (United States), ²Eli Lilly and Company - Indianapolis (United States)

THEME: Clinical Trials: Biomarkers including plasma

- P064** The ViewMind AI Solution (VIMAS) detects and characterises neurocognitive decline along the Alzheimer's disease continuum
Mario A. Parra¹, Francisco Lopera Restrepo², Gerardo Fernandez³, Danilo Verge⁴
¹University of Strathclyde - Glasgow (United Kingdom), ²Grupo de Neurociencias - Antioquia (Colombia), ³ViewMind - Bahia Blanca (Argentina), ⁴ViewMind - West Chester (United States)
- P065** Predicting cognitive stage transition using p-tau181, Centiloid, and other measures
Seong-Ho Koh¹, Hyuk Sung Kwon¹, Yongkyung Lee¹, Hyun-Jeung Yu², Seong Hye Choi², Hongil Kim¹
¹Hanyang University Guri Hospital - Guri (Korea, Republic of), ²Bundang Jesaeng Hospital - Seongnam (Korea, Republic of)
- P066** Relationship between brain amyloid deposition and regional electroencephalogram abnormalities in older adults
Woo Jung Kim¹, Jaesub Park²
¹Yonsei University College of Medicine - Yongin-Si, Gyeonggi-Do (Korea, Republic of), ²National Health Insurance Service Ilsan Hospital - Goyang-Si, Gyeonggi-Do (Korea, Republic of)
- P067** Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults
Seong-Ho Koh¹, Hyun-Jeung Yu², Kee Hyung Park³, Seong Hye Choi⁴
¹Department of Neurology, College of Medicine, Hanyang University - Guri (Korea, Republic of), ²Bundang Jesaeng Hospital - Seongnam (Korea, Republic of), ³Department of Neurology, College of Medicine, Gachon University Gil Medical Center - Incheon (Korea, Republic of), ⁴Department of Neurology, College of Medicine, Inha University Medical Center - Incheon (Korea, Republic of)
- P068** Direct Comparison of Four Blood Plasma-Based Biomarkers in Preclinical Alzheimer's Disease
Peter Snyder¹, Jessica Alber¹, Andreas Jeromin², Lauren Chaby², Stuart Portbury², Louisa Thompson³, Jennifer Strenger⁴, Ashley Price¹
¹The University of Rhode Island - Kingston (United States), ²ALZpath, Inc. - Carlsbad (United States), ³Alpert Medical School of Brown University - Providence (United States), ⁴Butler Hospital - Providence (United States)
- P069** Blood RNAs as fluid biomarkers for the differentiation between Alzheimer's disease and dementia with Lewy bodies
Katrin Beyer¹, Jorge Mena¹, David Adamuz¹, Dolores Vilas², Ispuerto Lourdes², Álvarez Ramiro², Pastor Pau²
¹Research Institute Germans Trias i Pujol - Badalona (Spain), ²Hospital Germans Trias i Pujol - Badalona (Spain)

- P070** **Systematic literature review of the clinical and non-clinical value of imaging and fluid biomarker testing to diagnose, identify and monitor patients with Alzheimer's Disease**
Salwa Masud ¹, Helen Hu ², Sreeranjani Menon ¹, Miya Strait ¹, Christian Siegfried ¹, Elizabeth Somers ², Catheline Plaideau ¹
¹Veranex - Boston (United States), ²Eisai Inc. - Nutley (United States)
- P071** **Serum Tau-A and Tau-C levels and their association with cognitive impairment and dementia progression in a memory clinic derived cohort**
Tobias Melton Axelsen ^{1,2,3}, Peter Høgh ^{4,5}, Asger Bihlet ⁶, Morten Asser Karsdal ², Kim Henriksen ², Steen Gregers Hasselbalch ⁷, Anja Hviid Simonsen ^{7,5}
¹Department of Biomedical Sciences, University of Copenhagen - Copenhagen (Denmark), ²Nordic Bioscience - Herlev (Denmark), ³Sanos Clinic, Herlev, Denmark - Herlev (Denmark), ⁴Regional Dementia Research Centre, Department of Neurology, Zealand University Hospital - Roskilde (Denmark), ⁵Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), ⁶NBCD - Søborg (Denmark), ⁷Danish Dementia Research Centre (DDRC), Department of Neurology, Rigshospitalet - Copenhagen (Denmark)
- P072** **Biomarker responses to gamma sensory stimulation in Alzheimer's disease patients assessed in HOPE clinical trial**
Mihaly Hajos ¹, Monika Shpokayte ¹, Celine Houser ¹, Evan Hempel ¹, Chandran Seshagiri ¹, Alyssa Galley ¹, Zach Malchano ¹, Ralph Kern ¹
¹Cognito Therapeutics - Cambridge (United States)
- P073** **A robust and specific ELISA for N-acetylated VAMP-2, a novel synaptic biomarker for Alzheimer's disease in CSF**
Charlotte De Rocker ¹, Julie Goossens ¹, Alba Cervantes Gonzalez ², Alberto Lleo ², Olivia Belbin ², Eugeen Vanmechelen ¹
¹ADx NeuroSciences - Gent(Zwijnaarde) (Belgium), ²CIBERNED - Madrid (Spain)
- P074** **Alzheimer's disease and microbiota: the MICMALZ cohort**
Germain Ulysse Busto ^{1,2}, Linda-Nora Mekki ³, Sylvaine Artero ³, Yves Dauvilliers ^{4,2}, Audrey Gabelle ¹, Karim Bennys ^{1,2}, Sylvie Claeysen ¹
¹Resource and Research Memory Center (CMRR), Department of Neurology, Montpellier University Hospital - Montpellier (France), ²University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), - Montpellier (France), ³The Institute of Functional Genomics (IGF), University of Montpellier, CNRS, INSERM, Montpellier, France - Montpellier (France), ⁴Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital - Montpellier (France)
- P075** **Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer's Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812**
Britney Lizama ¹, Eunah Cho ¹, Duc Duong ², Kiran Pandey ³, Claire Williams ¹, Anthony Caggiano ¹, Nicholas Seyfried ², Valentina Di Caro ¹, Mary Hamby ¹
¹Cognition Therapeutics, Inc - Pittsburgh (United States), ²Emory University School of Medicine - Atlanta (United States), ³Emtherapro, Inc. - Atlanta (United States)
- P076** **Associations between the NIH Toolbox Emotion Battery and Tau Pathology in Preclinical Alzheimer's Disease: Analysis of data from the multi-site ARMADA study**
Kexin Yu ¹, Jennifer Gatchel ², Emily Ho ³, Steven Arnold ⁴, Hiroko Dodge ⁴
¹Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University - Portland (United States), ²Department of Psychiatry, Massachusetts General Hospital/McLean Hospital, Harvard Medical School - Boston (United States), ³Department of Medical Social Sciences, Northwestern University - Evanston (United States), ⁴Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)
- P077** **Plasma protein markers to screen for blood-brain barrier dysfunction in Alzheimer's disease.**
Betty Tijms ¹
¹Amsterdam UMC - Amsterdam (Netherlands)
- P078** **A novel plasma CNS-derived tTau assay for detection of amyloid positivity in Alzheimer's Disease**
Gallen Triana-Baltzer ¹, Antonella Scaglione ¹, Setareh Moughadam ¹, Kristof Van Kolen ², Vanessa Raymond ³, Mark Woolrich ³, James Rowe ⁴, Hartmuth KoLP ¹
¹Janssen R&D - San Diego (United States), ²Janssen R&D - Beerse (Belgium), ³University of Oxford - Oxford (United Kingdom), ⁴University of Cambridge - Cambridge (United Kingdom)
- P079** **Pharmacodynamic Effects of Semorinemap on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer's Disease (Lauriet)**
Stephen Schauer ¹, Balaz Toth ¹, Julie Lee ¹, Veronica Anania ¹, Lee Honigberg ¹, Kristin Wildsmith ¹, Vidya Ramakrishnan ¹, Felix Yeh ¹, Michael Dolton ¹, Sandra Sanabria Bohorquez ¹, Edmond Teng ¹, Cecilia Monteiro ¹
¹Genentech - South San Francisco (United States)
- P080** **CSF proteomic insights into the mechanism of action of gamma sensory stimulation in Alzheimer's Disease**
Kiran Pandey ¹, Annabelle Singer ², Duc Duong ³, James Lah ³, Allan Levey ³, Nicholas Seyfried ³, Monika Spokayte ⁴, Zach Malchano ⁴, Mihaly Hajos ⁴
¹Emtherapro, Inc. - Atlanta (United States), ²Georgia Tech - Atlanta (United States), ³Emory University - Atlanta (United States), ⁴Cognito Therapeutics - Cambridge (United States)
- P081** **Changes in the neurology related CSF proteome after short-term treatment with XPro1595 for Alzheimer's disease**
Parris Pope ¹, Christopher Barnum ¹, Raymond Tesi ¹
¹Immune Bio, Inc. - Boca Raton (United States)

POSTER PRESENTATIONS

- P082** **A biomarker to aid Alzheimer's disease staging: sTREM2 is decreased in Amyloid positive/Tau negative, yet increased once Tau aggregates leading to increased cognitive decline**
Rodrigo Canovas¹, Christopher J. Fowler², Stephanie Rainey-Smith^{3,4,5,6}, Margherita Carboni⁷, Ivonne Suridjan⁷, Gwendlyn Kollmorgen⁸, Chad Logan⁹, Vincent Dore^{1,10}, Jurgen Fripp¹¹, Colin L. Masters², Qiao-Xin Li², Steven J. Collins¹², Paul Maruff¹³, **James D. Doecke**¹¹
¹Australian E-Health Research Centre, CSIRO, Parkville-Melbourne, Vic (Australia), ²The University of Melbourne, The Florey Institute-Melbourne, Vic (Australia), ³Centre for Healthy Ageing, Murdoch University - Murdoch, Wa (Australia), ⁴Australian Alzheimer's Research Foundation, - Perth, Wa (Australia), ⁵University of Western Australia - Perth, Wa (Australia), ⁶Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care-Joondalup, Wa (Australia), ⁷Roche Diagnostics International Ltd-Rotkreuz (Switzerland), ⁸Roche Diagnostics GmbH - Penzberg (Germany), ⁹Centralised & Point of Care Solutions, Roche Diagnostics GmbH-Penzberg (Germany), ¹⁰Department of Molecular Imaging & Therapy Austin Health-Melbourne, Vic (Australia), ¹¹Australian E-Health Research Centre, CSIRO-Brisbane, Qld (Australia), ¹²Department of Medicine & The Florey Institute, The University of Melbourne, Parkville-Melbourne, Vic (Australia), ¹³Cogstate Ltd-Melbourne, Vic (Australia)
- P083** **Sex Differences in Amyloid PET: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study**
Maison Abu Raya¹, Ehud Zeltzer¹, Isabel Elaine Allen¹, Maria Carrillo², Constantine Gatsonis³, Lucy Hanna⁴, Bruce E Hillner⁵, Leonardo Iaccarino¹, Andrew March⁶, Nidhi Mundada¹, Jhony Mejia Perez¹, Barry A Siegel⁷, Rachel A Whitmer⁸, Renaud La Joie¹, Gil Rabinovici¹
¹University of California San Francisco - San Francisco (United States), ²Alzheimer Association - Usa (United States), ³Brown University - Providence, Rhode Island (United States), ⁴Brown University - Providence, Rhode Island (United States), ⁵VCU Health - Virginia (United States), ⁶American College of Radiology - Philadelphia (United States), ⁷Washington University in St. Louis - St. Louis (United States), ⁸UCDAVIS - Davis (United States)
- P084** **The mastermind of the Alzheimer's blood-based biomarkers: development of cutoffs and a visualization tool for use in clinical dementia practice**
Charlotte Teunissen¹, Inge M.W. Verberk¹, Jolien Jutte^{1,2}, Maurice Y. Kingma^{1,2}, Argonde C. Van Harten^{1,3}, Anouk Den Braber^{1,3}, Sinthujah Vigneswaran^{1,4}, Mariam Gouda³, Marie-Paule Van Engelen³, Afina W. Lemstra³, Yolande A.L. Pijnenburg³, Wiesje M. Van Der Flier^{3,5}, Martijn Schut², David Wilson⁶
¹Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ²Translational Artificial Intelligence laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ³Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, - Amsterdam (Netherlands), ⁴Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, - Amsterdam (Pays-Bas) - Asmterdam (Netherlands), ⁵Amsterdam Public Health, Methodology & Digital Health - Amsterdam (Netherlands), ⁶Quanterix - Billerica (United States)
- P085** **AD risk genes for blood-brain barrier dysfunction**
Pieter Jelle Visser^{1,2,3}, Sven Van Der Lee¹, Charlotte Teunissen¹, Wiesje Vander Flier¹, Frode Berven⁴, Betty Tijms¹
¹Amsterdam UMC - Amsterdam (Netherlands), ²Maastricht University - Maastricht (Netherlands), ³Karolinska Institute - Stockholm (Sweden), ⁴University of Bergen - Norway (Netherlands)
- P086** **MIP-1 α serum levels correlate alongside positive outcome of clinical endpoints in Alzheimer's Disease patients receiving plasma exchange with albumin replacement**
Carla Minguet¹, Ricardo Gonzalo¹, Ana Ortiz¹, Isabel Bravo¹, Laura Núñez¹, Agustín Ruiz^{2,3}, Óscar López⁴, Mercè Boada^{2,3}, Antonio Páez¹, Montserrat Costa¹
¹Grifols - Barcelona (Spain), ²Universitat Internacional de Catalunya, Ace Alzheimer Centre Barcelona - Barcelona (Spain), ³Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) - Madrid (Spain), ⁴University of Pittsburgh School of Medicine - Pittsburgh (United States)
- P087** **Proteomic Analyses in the 24-Week PEGASUS Trial Using the Olink Platform: Providing Insight Into the Biologic Activity of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease**
Nicholas Cullen¹, Ryan Miller², Marcelo Gutierrez², Rudolph E. Tanzi³, **Lahar Mehta**²
¹BioFINDER Group, Department of Clinical Sciences, Lund University - Lund (Sweden), ²Amylyx Pharmaceuticals, Inc. - Cambridge (United States), ³Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University - Boston (United States)
- P088** **Statistical considerations for assessing the relationship between disease progression biomarkers and clinical endpoints in Alzheimer's disease**
Tianle Chen¹, R.matthew Hutchison¹, Carrie Rubel¹, Jennifer Murphy¹, Jing Xie¹, Philip Montenegro¹, Wenting Cheng¹, Kyle Fraser¹, Gersham Dent¹, John O'gorman¹, Suzanne Hendrix², Oskar Hansson³, Paul Aisen⁴, Ying Tian¹
¹Biogen - Cambridge, Ma (United States), ²Pentara Corporation - Millcreek, Ut (United States), ³Lund University - Malmö (Sweden), ⁴University of Southern California - San Diego, Ca (United States)
- P089** **Validation of clinical cutoffs for the beta-amyloid (Abeta42), p-Tau181 and p-Tau181/Abeta42 Roche Elecsys Generation 2 assays**
Joshua Bornhorst¹, Rebecca Deters¹, Jp Theobald¹, Alicia Algeciras-Schimmich¹
¹Mayo Clinic - Rochester (United States)
- P090** **Structural and functional DMN preservation after 24 weeks of rTMS in Alzheimer's disease patients**
Giacomo Koch¹, Lucia Mencarelli¹, Mario Torso², Martina Assogna¹, Federico Giove¹, Emiliano Santarnecchi³
¹Santa Lucia Foundation IRCCS - Rome (Italy), ²Oxford Diagnostics - Oxford (United Kingdom), ³MGH - Boston (United States)

- P092 Associations Between Blood-Based Biomarkers and Amyloid PET measurements in Cognitively Unimpaired Presenilin 1 E280A Mutation and Non-Mutation Carriers from the API Autosomal Dominant Alzheimer's Disease Colombia Prevention Trial**
Vedanshi Bhargava¹, Mike Malek-Ahmadi^{2,3,4}, Francisco Lopera⁵, Silvia Rios-Romenets⁵, Eugenia Cardona⁵, Yakeel T Quiroz-Gaviria⁶, Jessica Langabaum², Pierre Tariot², Robert Alexander², Yi Su^{2,1,7}, Kewei Chen^{2,3}, Tobias Bittner⁸, David Clayton⁸, Rachele Doody⁸, Eric Reiman^{2,9,10,1}
¹University of Arizona College of Medicine Phoenix - Phoenix (United States), ²Banner Alzheimer's Institute - Phoenix (United States), ³University of Arizona College of Medicine Phoenix - Phoenix (United States), ⁴Arizona Alzheimer's Consortium - Phoenix (United States), ⁵Neurosciences Group of Antioquia, Universidad de Antioquia - Medellin (Colombia), ⁶Massachusetts General Hospital and Harvard Medical School - Boston (United States), ⁷Arizona Alzheimer's Consortium - Phoenix (United States), ⁸Genentech - San Francisco (United States), ⁹Translational Genomics Research Institute - Phoenix (United States), ¹⁰Arizona Alzheimer's Consortium - Phoenix (United States)
- P093 Plasma p-tau217 as a cost-effective surrogate biomarker for clinical trials across the AD continuum**
Pamela C Lukasewicz Ferreira¹, Bruna Bellaver¹, Guilherme Povalá¹, Joao Pedro Ferrari-Souza¹, Firoza Z. Lussier¹, Douglas T. Leffa¹, Helmet Karim¹, Chang Hyung Hong², Hyun Woong Rho², Dana L. Tudorascu¹, Thomas K. Karikari¹, Beth E. Snitz³, Sang Joon Son², Tharick A Pascoal¹
¹Department of Psychiatry, School of Medicine, University of Pittsburgh - Pittsburgh (United States), ²Department of Psychiatry, Ajou University School of Medicine - Sowon (Korea, Republic of), ³Department of Neurology, School of Medicine, University of Pittsburgh - Pittsburgh (United States)
- P094 Plasma biomarkers and longitudinal cognitive decline in non-demented Alzheimer's disease**
Karly Cody¹, Rebecca Langhough¹, Lianlian Du¹, Erin Jonaitis¹, Nathaniel Chin¹, Beckie Jeffers¹, Monica Vandenlangenberg¹, Sanjay Asthana¹, Kris Kirmess², Matthew Meyer², Kevin Yarasheski², Tim West², Tobey Betthausen¹, Sterling Johnson¹
¹Wisconsin Alzheimer's Disease Research Center, University of Wisconsin - Madison (United States), ²C2N Diagnostics - St. Louis (United States)
- P095 Cerebrospinal fluid cellular transcriptomics as biomarkers of central nervous system drug-target engagement of a peripherally administered vaccine in older adults with and without cognitive impairment (BCG-AD)**
Marc Weinberg^{1,2}, Mahesh Kodali^{1,2}, Rojashree Jayakumar¹, Denise L. Faustman¹, Sudeshna Das^{1,2}, Steven Arnold^{1,2}
¹Mass General Hospital - Boston, MA (United States), ²Harvard Medical School - Cambridge, Ma (United States)
- P096 Bio-Hermes study topline results: AB 42/40 and p-Tau 181/217 blood-based biomarkers compared to amyloid PET and CSF in a diverse, community-based population**
Douglas Bearegard¹, Richard Mohs¹, John Dwyer¹, Sarah Hollingshead¹, Jennifer Gaudioso¹, Jason Bork¹, Diana Kerwin²
¹Global Alzheimer's Platform Foundation - Washington, Dc (United States), ²Kerwin Medical Center - Dallas (United States)
- LP043 Novel diagnostic platform enabling protein specific biomarker signature for the diagnosis of AD**
Marion San Nicolo¹, Oliver Peters², Hilary Wunderlich¹, Timo Grimmer³, Lutz Frölich⁴, Arno Schaepe¹, Richard Metzler¹, Sabine Mertzig¹, Klaus Hallermayer⁵, Harald Waltenberger⁶, Thomas Heydler¹, Mareike Haack¹
¹Noselab GmbH - Munich (Germany), ²Charite - Berlin (Germany), ³TUM - Munich (Germany), ⁴ZI Mannheim - Mannheim (Germany), ⁵GMX - Munich (Germany), ⁶Microcoat - Munich (Germany)
- LP044 A Cross-Sectional Study of Plasma Aβ42/40 ratio, p-Tau217, p-Tau181, GFAP and Nf-L in a Clinical Cohort Characterized by CNS Amyloid PET Imaging**
 Ahmed Chenna¹, Youssouf Badal¹, Mintzu Lo¹, Brandon Yee¹, Bryan Lim¹, Christopher Fowler², Robert Martone³, Christos Petropoulos¹, John Winslow¹
¹Labcorp-Monogram Biosciences - South San Francisco, Ca (United States), ²The Florey Institute of Neuroscience and Mental Health - Parkville, VIC (Australia), ³Labcorp Drug Development - Indianapolis, IN (United States)
- LP046 Analytical Validation and Initial Clinical Evaluation of a New Blood-Based Diagnostic Test for Alzheimer's Disease**
 Andrew Schade¹, Adam Abel¹, Antonio Chambers¹, Jeff Fill¹, Heinz Reiske¹, Ming Lu¹, Amanda Morris¹, Michael Pontecorvo¹, Emily Collins¹, Mark Mintun¹, Michael Hodsdon¹
¹Eli Lilly and Company - Indianapolis (United States)
- LP047 Analytical and Clinical Validation of β-Amyloid 1-40, 1-42, and the 1-42/1-40 Ratio using a Clinical Autoanalyzer**
Ayla Harris¹, Tien Le¹, Bradley Collier¹, Matthew Chappell¹, Deborah Boles¹, Russell Grant¹
¹Labcorp - Burlington (United States)
- LP048 The Alzheimer's Association Global Biomarker Standardisation Consortium (GBSC) plasma phospho-tau Round Robin study**
Nicholas Ashton¹, Ashvini Keshavan², Lana Grötschel¹, Les Shaw³, Kaj Blennow⁴, Jonathan Schott⁵, Henrik Zetterberg⁶
¹University of Gothenburg - Göteborg (Sweden) - Göteborg (Sweden), ²University College London - London (United Kingdom) - London (United Kingdom), ³University of Pennsylvania - Philadelphia (United States) - Philadelphia (United States), ⁴University of Pennsylvania - Philadelphia (United States), ⁵University College London - London (United Kingdom), ⁶University of Gothenburg - Göteborg (Sweden)
- LP049 Gene Expression Profile of Synchronized Cells Identifies Alzheimer's Disease in Autopsy Validated Skin and Blood Samples**
Florin Chirila^{1,2}, Macturk William¹, Wallace Jack¹, Xu Guang¹, Alkon Daniel¹
¹Synaps Dx - Rockville (United States), ²Spot Dx - Morgantown (United States)

POSTER PRESENTATIONS

- LP051 **Investigating Sex-Specific Blood Biomarkers Associated with Memory Changes in Middle-Aged Adults: Insights from the Framingham Heart Study**
Huitong Ding¹, Chunyu Liu², Yi Li², Ting Fang Alvin Ang¹, Sherral Devine¹, Yulin Liu¹, Rhoda Au¹, P. Murali Doraiswamy³
¹Boston University Chobanian & Avedisian School of Medicine - Boston (United States), ²Boston University School of Public Health - Boston (United States), ³Duke University School of Medicine - Boston (United States)
- LP052 **Validation of an Ultra-Sensitive Method for Phospho-Tau 217 (pTau-217) Quantitation in Human Plasma, Serum, and CSF**
Hongming Zhang¹, Jialu Liu¹, Nan Zhang¹, Zhongping John Lin¹
¹Frontage Laboratories Inc. - Exton (United States)
- LP053 **Prediction of Amyloid PET positivity from blood-based biomarkers and clinical data using AI-based Digital Twins**
 Wenjun Zhu¹, So-Youn Shin¹, Jeanne Latourelle¹
¹Aitia - Somerville (United States)
- LP054 **Changes of CSF and plasma biomarkers during 18-month period in a phase II clinical trial with biomarker proven Alzheimer's disease patients**
Charlotte Teunissen¹, Marleen Koel-Simmeling¹, Marlies Oosthoek¹, Niels Prins², Pieter Van Bokhoven³, Tomohiro Okuda⁴, Philip Scheltens⁵
¹Neurochemistry Laboratory, Department of Neurochemistry, Amsterdam UMC - Amsterdam (Netherlands), ²Brain Research Center - Amsterdam (Netherlands), ³IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), ⁴FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), ⁵Amsterdam UMC - Amsterdam (Netherlands)
- LP055 **Analytical and clinical validation of the Simoa Janssen plasma p217+ Tau as a CLIA lab developed test (LDT) for clinical use**
David Wilson¹, Gallen Triana-Baltzer², Ann-Jeanette Vasko¹, Karen Copeland³, Lyndal Hesterberg⁴, Meenakshi Khare¹, Michele Wolfe¹, Patrick Sheehy¹, Zachary Fernandes¹, Hartmuth KoLP², Mark Roskey¹, Mark Miller¹
¹Quanterix - Billerica (United States), ²Janssen R&D - La Jolla (United States), ³Boulder Statistics - Steamboat Springs (United States), ⁴HCS, Inc - Denver (United States)
- LP056 **The role of neuroinflammation in Alzheimer's disease: A systematic literature review**
 Michael T. Heneka¹, Serge Gauthier², Chandekar Anil Sagar³, Julie Hahn-Pedersen Hviid³, Marie Bentsen³, Henrik Zetterberg⁴
¹Luxembourg Centre for Systems Biomedicine, Université du Luxembourg - Belvaux (Luxembourg), ²AD and Related Disorders Research Unit, McGill Center for Studies in Aging, Departments of Neurology & Neurosurgery, Psychiatry, and Medicine at McGill - Montreal (Canada), ³Novo Nordisk A/S - Søborg (Denmark), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden)
- LP057 **Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer's Disease Patients**
 Valentina Di Caro¹, Kiran Pandey², Britney Lizama¹, Eunah Cho¹, Duc Duong^{3,4}, Willem De Haan^{5,6}, Michael Grundman⁷, Nicholas Seyfried⁴, Anthony Caggiano¹, Everard Vijverberg⁶, Mary Hamby¹
¹Cognition Therapeutics, Inc. - Pittsburgh (United States), ²Emtherapro Inc, Systems Biology. - Atlanta (United States), ³Emtherapro Inc, Systems Biology - Atlanta (United States), ⁴Emory University School of Medicine, Biochemistry - Atlanta (United States), ⁵Department of Clinical Neurophysiology and MEG Center, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁶Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ⁷Global R&D Partners, LLC and Dept of Neurosciences University of California - San Diego (United States)
- LP058 **Changes in EEG theta/alpha ratio during an 18-month period in a phase II clinical trial with biomarker-confirmed Alzheimer's disease patients**
Willem De Haan¹, Niels Prins², Pieter Van Bokhoven³, Tomohiro Okuda⁴, Philip Scheltens⁵
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), ²Brain Research Center - Amsterdam (Netherlands), ³IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), ⁴FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), ⁵Amsterdam UMC - Amsterdam (Netherlands)
-  LP059 **Assessment of plasma biomarkers combined with clinical measures in mild cognitive impairment, AD dementia, and normal aging**
Marwan Sabbagh¹, Megan Thomas¹, Jeffrey Wilson², Giovanni Malaty¹, Boris Decourt³
¹Barrow Neurological Institute - Phoenix (United States), ²Arizona State University - Tempe (United States), ³Texas Tech University - Lubbock (United States)
-  LP060 **Multiomeric Blood-Based Biomarkers Exhibit High Specificity in Predicting Alzheimer's Disease from Predementia**
 Benoit Souchet¹, Alkeos Michail¹, Maud Heuillet², Aude Dupuy-Gayral², Eloi Haudebourg², Catherine Pech², Antoine Berthemy², François Autelitano², Baptiste Billoir¹, Kimiko Domoto-Reilly³, Christopher Fowler⁴, Thomas Grabowski³, Suman Jayadev³, Colin L. Masters⁴, Jerome Braudeau¹
¹AgentT - Paris (France), ²Evotec - Toulouse (France), ³University of Washington - Seattle (United States), ⁴University of Melbourne - Victoria (Australia)

THEME: Clinical Trials: Cognitive and functional endpoints

- P098 **Between-Country Comparisons of Quality of Life and Activities of Daily Living in Multinational Alzheimer's Disease Clinical Trials**
Sayaka Machizawa¹, Erica Appleman¹, Jessica Stenclik¹, Andrei Iacob², Rujvi Kamat¹
¹Signant Health - Blue Bell (United States), ²Signant Health - Bucharest (Romania)
- P099 **The Effect of Global Functioning on Participant and Study Partner Ratings of Quality of Life in Participants with Prodromal to Mild Alzheimer's Disease**
Jessica Stenclik¹, Amanda Aedo¹, Sayaka Machizawa¹, Rujvi Kamat¹, Erica Appleman¹, Andrei Iacob¹
¹Signant Health - Blue Bell (United States)
-  P100 **Blood pressure variability via ambulatory monitoring and risk for dementia in the SPRINT MIND trial**
Isabel Sible¹, Daniel Nation²
¹University of Southern California - Los Angeles (United States), ²University of California Irvine - Irvine (United States)
- P101 **Longitudinal resting-state EEG along the Alzheimer's disease continuum: the road to successful clinical trial implementation**
Elliz P. Scheijbeler¹, Willem De Haan¹, Cornelis J. Stam¹, Jos W. R. Twisk¹, Alida A. Gouw¹
¹Amsterdam UMC location VUmc - Amsterdam (Netherlands)
- P102 **The EEG as functional endpoint in AD trials**
Willem De Haan^{1,2}, Elliz Scheijbeler^{1,2}, Alida Gouw^{1,2,3}, Cornelis Jan Stam^{4,2}
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), ²Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), ³Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, - Amsterdam (Netherlands), ⁴Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands)
- P103 **Rates of Progression in Patients with Alzheimer's Disease Depending on Apolipoprotein E Genotype and Concomitant Medications**
Carina Wattmo¹
¹Cognitive Disorders Research Unit, Department of Clinical Sciences, Malmö, Lund University - Malmö (Sweden)
- P104 **Effects of Melissa officinalis extract containing rosmarinic acid for Alzheimer's disease in human**
Moeko Shinohara¹, Kenjiro Ono¹
¹Kanazawa University - Kanazawa (Japan)
- P105 **TRAILBLAZER-ALZ 2: Heterogeneity in performance of clinical outcome assessments across geo-cultural areas**
Giulia Tronchin¹, Wendy Wenyu Ye¹, Xiaojuan Mi², Alette M. Wessels¹
¹Eli Lilly and Company - Indianapolis (United States), ²TechData Services Company - King Of Prussia (United States)
- P106 **Assessing 'true' non-progression rate in early Alzheimer's disease accounting for within-subject variation**
Menglan Pang¹, Willem Huijbers¹, Audrey Gabelle¹, Arie Gafson¹, Richard Hughes¹, Shibeshih Belachew¹, Shen Changyu¹
¹Biogen - Cambridge (United States)
- P107 **Video-based Assessment of Cognitive Frailty in Older Adults with Cognitive Impairment**
Ram Kinker Mishra¹, Myeounggon Lee², Jaewon Beom², Mohammad Dehghan Rouzi², Ashkan Vaziri¹, Bijan Najafi²
¹BioSensics LLC - Boston (United States), ²Baylor College of Medicine - Houston (United States)
- P108 **Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies**
 Peter Høgh¹, Michael Fischer¹
¹Department of Neurology, Zealand University Hospital - Roskilde (Denmark)
- P109 **Timing the change in the Pre-clinical Alzheimer's Cognitive Composite score with Amyloid-β in pre-clinical Alzheimer's Disease**
 Timothy Cox¹, Rosita Shishegar¹, Christopher Fowler², Stephanie Rainey-Smith^{3,4,5,6}, Hamid Sohrabi^{3,4}, Shaun Markovic^{3,4}, Vincent Dore^{1,7}, Pierrick Bourgeat⁸, Jurgen Fripp⁸, Ralph Martins^{6,9}, Victor Villemagne¹⁰, Colin Masters², Christopher Rowe^{2,7}, James Doecke⁸
¹Australian E-Health Research Centre, CSIRO - Parkville (Australia), ²The University of Melbourne, The Florey Institute - Melbourne (Australia), ³Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), ⁴Australian Alzheimer's Research Foundation - Perth (Australia), ⁵University of Western Australia - Perth (Australia), ⁶Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care - Perth (Australia), ⁷Department of Molecular Imaging & Therapy Austin Health - Melbourne (Australia), ⁸Australian E-Health Research Centre, CSIRO - Brisbane (Australia), ⁹Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University - Sydney (Australia), ¹⁰Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States)
- P110 **Impact of study partner type on primary endpoint variability in two phase 3 registration trials in mild-to-moderate Alzheimer's disease**
Mary Ryan^{1,2,3}, Daniel Gillen^{1,2}, Joshua Grill^{1,4,5}
¹Institute for Memory Impairments and Neurological Disorders, UC Irvine - Irvine (United States), ²Department of Statistics, UC Irvine - Irvine (United States), ³Department of Biostatistics, Yale School of Public Health - New Haven (United States), ⁴Department of Psychiatry and Human Behavior, UC Irvine - Irvine (United States), ⁵Department of Neurobiology and Behavior, UC Irvine - Irvine (United States)
- P111 **Effects of phytoncide inhalation on Stroop task performance in patients with mild cognitive impairment: an fNIRS pilot study**
 Do Hoon Kim¹, Seungchan Park¹, Jiheon Kim¹
¹Chuncheon Sacred Heart Hospital Hallym University College of Medicine - Chuncheon (Korea, Republic of)
- P112 **The use of composite z-scores in place of normative-based scaling to improve signal detection in clinical trials involving neurodegenerative diseases**
Erin Jacobs¹, Christopher Randolph^{1,2}, Danielle Digregorio¹, Selam Negash¹, Raymond Blattner¹
¹WCG Clinical - Princeton (United States), ²Loyola University Medical Center - Chicago (United States)

POSTER PRESENTATIONS

- P113** **The Expanded Brief Assessment of Cognition (BAC) for the Assessment of Cognitive Impairment in Mild Alzheimer's Disease**
Dorothee Schoemaker¹, Alexandra S. Atkins¹, Chelsea Abraham¹, Haley Evans¹, Matthew Welch¹, Brenda L. Plassman², Corrine Madsen², Nancy Sichel², Jan Sedway¹, Kathleen A. Welsh-Bohmer¹, Rich S.e. Keefe¹
¹WCG - Cary (United States), ²Duke University - Durham (United States)
- P114** **Standardized Implementation of Personalized Endpoints Following FDA's Draft Guidance 4 on Patient-Focused Drug Development: Goal Attainment Scaling in a Phase 2 Study of Xpro in Patients with Early Alzheimer's Disease**
 Gunes Sevinc¹, Chere Chapman¹, Tara Lehner², Christopher Barnum², Judith Jaeger^{2,3,4}, Kenneth Rockwood^{1,5,6}
¹Ardea Outcomes - Nova Scotia (Canada), ²Inmune Bio, Inc - Florida (United States), ³CognitionMetrics, LLC - Connecticut (United States), ⁴Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine - New York (United States), ⁵Division of Geriatric Medicine, Dalhousie University, - Nova Scotia (Canada), ⁶Geriatric Medicine Research Unit, Nova Scotia Health Authority, - Nova Scotia (Canada)
- P115** **Verbal Learning Over Five Days: Learning Curves, Age-Independence, and Sleep Sensitivity**
 Alexander Kaula¹, Nicholas Taptiklis¹, Naim Sen¹, Francesca Cormack^{1,2}, Nathan Cashdollar¹, Kenton Zavitz¹
¹Cambridge Cognition - Cambridge (United Kingdom), ²University of Cambridge - Cambridge (United Kingdom)
- P116** **A Meta-Analysis to Demonstrate the Incidence of Placebo Effect in Alzheimer's Disease and Mild Cognitive Impairment Trials: Mitigating for Impacts on Trial Endpoints**
Melissa Carbo¹, Madelyn Moberg¹, Rolana Avrumson¹
¹Worldwide Clinical Trials - Doylestown (United States)
- P117** **Capturing clinically meaningful change in Alzheimer's disease: the electronic Person Specific Outcome Measure approach**
Álvaro Pascual-Leone^{1,8}, Stina Saunders^{1,2}, Joyce Gomes-Osman^{1,3}, Ali Jannati^{1,4}, Sean Tobyne¹, Jeff Pobst¹, Craig Ritchie^{5,6}, Saturnino Luz², Graciela Muniz-Terrera^{2,7}
¹Linus Health Inc - Boston (United States), ²University of Edinburgh - Edinburgh (United Kingdom), ³University of Miami Miller School of Medicine - Miami (United States), ⁴Harvard Medical School - Boston (United States), ⁵Scottish Brain Sciences - Edinburgh (United Kingdom), ⁶University of Edinburgh - Edinburgh (United Kingdom) - Edinburgh (United Kingdom), ⁷University of Ohio - Ohio (United States), ⁸Hebrew SeniorLife - Boston (United States)
- LP062** **Tracking short-term cognitive changes among cognitively unimpaired older adults with different amyloid (A) and tau (T) profiles using The Boston Remote Assessment for Neurocognitive Health (BRANCH)**
Roos Jutten¹, Daniel Soberanes², Emma Weizenbaum¹, Cassidy Molinare¹, Stephanie Hsieh¹, Michelle Farrell¹, Dorene Rentz^{1,2}, Gad Marshall^{1,2}, Keith Johnson¹, Reisa Sperling^{1,2}, Rebecca Amariglio^{1,2}, Kate Papp^{1,2}
¹Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Brigham and Women's Hospital, Harvard Medical School - Boston (United States)
- LP063** **Factors associated with floor and ceiling effects in the LatAm-FINGERS neuropsychological battery**
Monica Yassuda¹, Claudia Suemoto¹, Lucia Crivelli², Ismael Calandri², Paulo Caramelli³, Francisco Lopera⁴, Sonia Brucki¹, Ricardo Nitrini¹, Ana Luisa Sosa⁵, Rosa Salinas⁵, Lina Velilla⁴, Gustavo Sevlever², Mii Kivipelto⁶, Maria Carrillo⁷, Ricardo Allegri²
¹University of São Paulo - São Paulo (Brazil), ²Fleni - Buenos Aires (Argentina), ³Universidad Federal de Minas Gerais - Belo Horizonte (Brazil), ⁴Antioquia Medical School - Antioquia (Colombia), ⁵Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez - Ciudad De México (Mexico), ⁶Karolinska Institutet - Stockholm (Sweden), ⁷Alzheimer's Association - Chicago (United States)
- LP064** **Robustness and generalizability of a speech based composite score for measuring disease progression in AD**
 Michael Spilka¹, Mengdan Xu¹, Jessica Robin¹, William Simpson¹
¹Winterlight Labs - Toronto (Canada)
- LP065** **Cognitive Functional Composite detected time-dependent worsening of cognition and function during 18-month period in a phase II clinical trial with biomarker proven Alzheimer's disease patients**
Sietske Sikkes¹, Merel Postema¹, Niels Prins², Pieter Van Bokhoven³, Tomohiro Okuda⁴, Philip Scheltens⁵
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), ²Brain Research Center - Amsterdam (Netherlands), ³IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), ⁴FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), ⁵Amsterdam UMC - Amsterdam (Netherlands)
-  **LP067** **Measuring What Matters Most to People Living With Alzheimer's Disease and Care Partners: What Matters Most Qualitative Research**
 Carla Romano¹, Emily Bratlee-Whitaker¹, William L Herring^{1,2}, Leigh F Callahan³, Karina Raimundo⁴, Jim Taylor⁵, Geri Taylor⁵, Ian Kremer⁶, Debra Lappin², Terry Frangiosa⁷, Kajan Gnanasakthy¹, Diana Goss¹, Russ Paulsen⁸, Ann Hartry⁹, Dana Dibenedetti¹
¹RTI Health Solutions - Research Triangle Park (United States), ²Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), ³University of North Carolina at Chapel Hill - Chapel Hill (United States), ⁴Genentech - San Francisco (United States), ⁵Memory Advocate Peers (MAP) - New York (United States), ⁶LEAD Coalition (Leaders Engaged on Alzheimer's Disease) - Washington, D. C. (United States), ⁷Faegre Drinker Consulting - Washington, D. C. (United States), ⁸UsAgainstAlzheimer's - Washington, D. C. (United States), ⁹Biogen Inc - Cambridge (United States)
-  **LP068** **The Down Syndrome – Clinical Global Impression of Change (DS-CGIC)**
 Julian Gray¹, Andre Strydom², Olivier Sol¹, Juan Fortea³, Michael Rafii⁴
¹AC Immune - Lousanne (Switzerland), ²King's College - London (United Kingdom), ³Hospital San Pau - Barcelona (Spain), ⁴USC - San Diego (United States)
-  **LP069** **The Longitudinal Impact of COVID-19 Lockdown on Mild Cognitive Impairment and Alzheimer's Disease**
Hahyun Lee^{1,2}, Yoon-Soo Cho³, Jun-Young Lee¹
¹Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea - Seoul (Korea, Republic of), ²Interdisciplinary Program in Cognitive Science, Seoul National University, Republic of Korea Interdisciplinary Program in Cognitive Science - Seoul (Korea, Republic of), ³Keimyung University School of Medicine & Institute for Medical Science - Daegu (Korea, Republic of)



THEME: Cognitive assessment and clinical trials

- P118** **The ViewMind AI Solution (VIMAS) addresses inequities and disparities in the assessment of dementia risk**
 Mario A. Parra ¹, Alfredis Gonzalez-Hernandez ², Jasmin Bonilla-Santos ², Rodrigo A. Gonzalez-Montealegre ², Dorian Yisela-Cala ², Gerardo Fernandez ³, Danilo Verge ⁴
¹University of Strathclyde - Glasgow (United Kingdom), ²Universidad Surcolombiana - Huila (Colombia), ³ViewMind - Bahia Blanca (Argentina), ⁴ViewMind - West Chester (United States)
- P119** **Clinical Dementia Rating Scale (CDR®) domain scores differ by diagnosis in Hispanic and non-Hispanic White samples**
 Giovanna Pilonieta ¹, David Geldmacher ¹
¹The University of Alabama at Birmingham - Birmingham (United States)
- P120** **Sex bias and the association of dementia lifestyle risk factors with superager status**
 Matthew Mcphee ¹, Larissa Mcketton ², Annalise Laplume ³, Angela Troyer ^{1,4}, Nicole Anderson ^{2,4,5}
¹Neuropsychology and Cognitive Health, Baycrest - Toronto (Canada), ²Rotman Research Institute, Baycrest Academy for Research and Education - Toronto (Canada), ³Douglas Research Centre, McGill University and Centre for Research at the Geriatrics Institute of the University of Montreal - Montreal (Canada), ⁴Department of Psychology, University of Toronto - Toronto (Canada), ⁵Department of Psychiatry, University of Toronto - Toronto (Canada)
- P121** **Objective Monitoring of Instrumental Activities of Daily Living in Dementia**
Ram Kinker Mishra ¹, Myeounggon Lee ², Adonay S. Nunes ¹, Michele K. York ², Mark E. Kunik ², Ashkan Vaziri ¹, Bijan Najafi ²
¹Biosensics - Boston (United States), ²Baylor College of Medicine - Houston (United States)
- P122** **Errors in Clinical Dementia Rating administration and scoring: Identifying targets for intervention**
Rujvi Kamat ¹, Jacqueline Massa ¹, Amanda Aedo ¹, Gila Barbati ¹, Sayaka Machizawa ¹, Jessica Stenclik ¹, Erica Appleman ¹, Andrei Iacob ¹
¹Signant Health - Blue Bell (United States)
- P123** **Leveraging AI methods to detect cognitive decline and dementia over the telephone: a promising new screening tool**
Catherine Diaz-Asper ¹, Chelsea Chandler ², R. Scott Turner ³, Brigid Reynolds ³, Brita Elvevåg ⁴
¹Marymount University - Arlington (United States), ²University of Colorado, Boulder - Boulder (United States), ³Georgetown University - Washington Dc (United States), ⁴University of Tromsø - the Arctic University of Norway - Tromsø (Norway)
-  **P124** **Influence of COVID-19 pandemic to self-perceived memory decline: contribution to cognitive change one-year later**
Kenichiro Sato ^{1,2}, Yoshiki Niimi ², Ryoko Ihara ³, Kazushi Suzuki ⁴, Atsushi Iwata ³, Takeshi Iwatsubo ^{1,2}
¹University of Tokyo - Tokyo (Japan), ²University of Tokyo Hospital - Tokyo (Japan), ³Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan), ⁴National Defense Medical College - Saitama (Japan)
- P125** **Nili: Digital Health Solution for Dementia Care Coordination and Management**
 Ram Kinker Mishra ¹, Myeounggon Lee ^{2,3}, Michele K. York ³, Mark E. Kunik ^{4,5}, Bijan Najafi ^{2,3}, Ashkan Vaziri ¹
¹BioSensics LLC - Newton (United States), ²Department of Surgery, Baylor College of Medicine - Houston (United States), ³Neurology and Psychiatry & Behavioral Sciences, Baylor College of Medicine - Houston (United States), ⁴Menninger Department of Psychiatry and Behavioral Science, Baylor College of Medicine - Houston (United States), ⁵Michael E. DeBakey Veterans Affairs Medical Center - Houston (United States)
- P126** **Using Speech Biomarkers for Detection and Monitoring of Cognitive Decline**
 Adonay S. Nunes ¹, Gozde Cay ², Myeounggon Lee ², Mohammad Dehghan Rouzi ², Nesreen El-Refaei ², Anmol Momin ², Ram Kinker Mishra ¹, Bijan Najafi ², Ashkan Vaziri ¹
¹BioSensics LLC - Boston (United States), ²Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine - Houston (United States)
- P127** **Validation of a TICS-m cutoff score for identification of cognitive impairment during telephone pre-screening assessment**
Eric Fischer ¹, Abigail O'connell ², Sarah Gaussoin ³, Samuel Lockhart ¹, Suzanne Craft ¹
¹Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States), ²Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States) - Winston-Salem (United States), ³Wake Forest School of Medicine, Department of Biostatistics and Data Science - Winston-Salem (United States)
- P128** **The Pre-Clinical Alzheimer's Cognitive Composite Score: Informing Clinical Meaningfulness through the Alzheimer's Disease Continuum**
James David Doecke ¹, Marcela Cespedes ¹, Timothy Cox ², Rosita Shishegar ³, Christopher James Fowler ⁴, Stephanie Rainey-Smith ^{5,6,7,8}, Hamid Sohrabi ^{9,10}, Shaun Markovic ^{9,10}, Jurgen Frupp ¹, Cai Gillis ¹¹, Nancy Maserejian ¹¹, Yen Ying Lim ¹², Jason Hassenstab ^{13,14}, Paul Maruff ¹⁵
¹Australian E-Health Research Centre, CSIRO - Herston (Australia), ²Australian E-Health Research Centre, CSIRO - Canberra (Australia), ³Australian E-Health Research Centre, CSIRO - Parkville (Australia), ⁴The University of Melbourne, The Florey Institute - Parkville (Australia), ⁵Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), ⁶Australian Alzheimer's Research Foundation - Perth (Australia), ⁷University of Western Australia - Perth (Australia), ⁸Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care - Joondalup (Australia), ⁹Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), ¹⁰Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), ¹¹Biogen - Boston (United States), ¹²Turner Institute for Brain and Mental Health, School of Psychological Sciences - Monash (Australia), ¹³Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), ¹⁴Department of Neurology, Washington University School of Medicine - St. Louis (United States), ¹⁵Cogstate - Melbourne (Australia)

POSTER PRESENTATIONS

- P129 Automated linguistic metrics from a novel, remote, smartphone-based self-assessment of cued narration and free recall correlate with brain atrophy in language and memory networks in early Alzheimer's disease**
Irma T. Kurniawan¹, Michał K. Kosek², Raphael M. Ullmann¹, Arnaud M. Wolfer¹, Stefan Holiga¹, Eduardo A. Aponte¹, Thanneer M. Perumal¹, Kirsten I. Taylor¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ²Roche Global IT Solution Centre, Warsaw, Poland - Warsaw (Poland)
- P130 Characterising progressive decline across multiple cognitive domains in preclinical Alzheimer's disease**
Rosita Shishegar¹, Timothy Cox², Hamid R. Sohrabi³, Shaun Markovic³, Jurgen Fripp⁴, Vincent Doré¹, Pierrick Bourgeat⁴, Jason Hassenstab⁵, Yen Ying Lim⁶, Paul Maruff⁷, Colin L. Masters⁸, James D Doecke⁸
¹Australian E-Health Research Centre, CSIRO - Melbourne (Australia), ²Australian E-Health Research Centre, CSIRO - Canberra (Australia), ³Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), ⁴Australian E-Health Research Centre, CSIRO - Brisbane (Australia), ⁵Department of Psychological and Brain Sciences, Washington University in Saint Louis - Saint Louis (United States), ⁶Turner Institute of Brain and Mental Health, School of Psychological Sciences, Monash University - Clayton (Australia), ⁷Cogstate Ltd. - Melbourne (Australia), ⁸The University of Melbourne, The Florey Institute - Melbourne (Australia)
- P131 Do Alzheimer's Risk Genes Also Predict Cognitive Decline?**
Shane Fernandez^{1,2}, Rosita Shishegar³, Paul Maruff^{4,5}, Colin Masters⁴, Victor Villemagne^{6,7}, Timothy Cox³, Vincent Doré^{3,7}, Tenielle Porter^{1,2}, Simon Laws^{1,2}
¹Centre for Precision Health, Edith Cowan University - Perth (Australia), ²Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University - Perth (Australia), ³Australian E-Health Research Centre, CSIRO - Melbourne (Australia), ⁴Florey Institute of Neuroscience and Mental Health, The University of Melbourne - Melbourne (Australia), ⁵Cogstate Ltd - Melbourne (Australia), ⁶Department of Psychiatry, University of Pittsburgh, - Pittsburgh (United States), ⁷Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, - Melbourne (Australia)
- P132 Forecasting Future Dementia Risk Using a Digital Clock Drawing Assessment in an African American Population**
Jeff Pobst¹, Sean Tobyné¹, Ali Jannati^{1,2}, Russell Banks^{1,3}, David Libon^{1,4}, Rodney Swenson^{1,5}, Melissa Lamar^{6,7}, Lisa Barnes^{6,7,8}, David Bates¹, John Showalter¹, Alvaro Pascual-Leone^{1,2,9}
¹Linus Health, Inc. - Boston, Massachusetts (United States), ²Department of Neurology, Harvard Medical School - Cambridge, Massachusetts (United States), ³Michigan State University - East Lansing, Michigan (United States), ⁴Rowan University - Stratford, New Jersey (United States), ⁵University of North Dakota School of Medicine and Health Sciences - Fargo, North Dakota (United States), ⁶Rush Alzheimer's Disease Center - Chicago, Illinois (United States), ⁷Department of Psychiatry and Behavioral Sciences, Rush University Medical Center - Chicago, Illinois (United States), ⁸Department of Neurological Sciences, Rush University Medical Center - Chicago, Illinois (United States), ⁹Hinda and Arthur Marcus Institute for Aging Research, Deanna and Sidney Wolk Center of Memory Health, Hebrew Senior Life - Boston, Massachusetts (United States)
- P133 Bridging the Assessment Gap: Newly Developed Neuropsychiatric Cognitive Assessments on the Cognivue® Platform Show Strong Correlation with Traditional Gold Standard Tests**
James Galvin¹
¹University of Miami Comprehensive Center for Brain Health - Miami (United States)
- P134 Efficient and Automated Cognitive Pre-Screening for Clinical Trials using the Montreal Cognitive Assessment (MoCA) Xpresso Tool and Automated Report**
Sivan Klil-Drori¹, Katie Bodenstein², Lara Kojok², Shuo Mila Sun³, Youssef Ghantous², Ziad Nasreddine²
¹McGill University - Montreal, Qc (Canada), ²MoCA Cognition Clinic and Institute - Montreal, Qc (Canada), ³Harvard University - Cambridge, Ma (United States)
- P135 Attaching clinical meaningfulness to CDR-SB score**
Danielle Digregorio¹, Christopher Randolph^{1,2}, Dorothee Shoemaker¹, Selam Negash¹, Erin Jacobs¹, Raymond Blattner¹
¹WCG - Princeton (United States), ²Loyola University Medical Center - Chicago (United States)
- P136 Analysis of Aβ(1-42) Oligomers by Cyclic Ion Mobility SPECTROMETRY in spiked HUMAN cerebrospinal fluid**
Mikuláš Vlk¹, John Hey², Walter Korfmacher², Alexander Muck³, Martin Hubálek¹, Josef Cvačka¹
¹Institute of Organic Chemistry and Biochemistry of the CAS, Mass Spectrometry Group - Prague (Czech Republic), ²Alzheon - Framingham (United States), ³Waters Corporation, Analytical Professional Services EMEA - Wilmslow (United Kingdom)
- P137 Sex Differences in Predicting Progression in Cognitively Unimpaired ADNI Participants Using Cognitive Test Performance**
Adam Diaz^{1,2}, Melanie J. Miller^{1,2}, Marta Mila Aloma^{1,3}, Zack Hausle^{1,3}, Pamela Zobel-Thropp^{1,3}, Duygu Tosun³, Rachel Nosheny⁴, Leslie M. Shaw⁵, Michael W. Weiner^{1,2}
¹Northern California Institute for Research and Education (NCIRE) - San Francisco (United States), ²Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases - San Francisco (United States), ³University of California, San Francisco, Department of Radiology and Biomedical Imaging - San Francisco (United States), ⁴University of California, San Francisco, Department of Psychiatry and Behavioral Sciences - San Francisco (United States), ⁵University of Pennsylvania, Perelman School of Medicine - Pennsylvania (United States)



- LP070** **Association of Speech and Language features with Biomarkers in Early Stage Alzheimer patients**
Alexandra König^{1,2}, Stefanie Köhler³, Johannes Tröger¹, Elisa Mallick¹, Nicklas Linz¹, Josef Priller^{4,5,6,7}, Markus Donix^{8,9}, Jens Wiltfang^{10,11,12}, Inga Zerr^{10,13}, Düzel Düzel^{14,15,16}, Annika Spottke^{17,18}, Frederic Brosseron¹⁹, Michael Wagner^{19,20}, Alfredo Ramirez^{19,20,21,22}, Stefan Teipel^{3,23}
¹ki:elements GmbH - Saarbrücken (Germany), ²Cobtek (Cognition-Behaviour-Technology), Université Côte d'Azur, e - Nice (France), ³Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Standort Rostock/Greifswald, - Rostock/greifswald (Germany), ⁴Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Berlin (Germany), ⁵Department of Psychiatry and Psychotherapy, Charitéy - Berlin (Germany), ⁶School of Medicine, Technical University of Munich; Department of Psychiatry and Psychotherapy, - Munich (Germany), ⁷University of Edinburgh and UK DRI, - Edinburgh (United Kingdom), ⁸Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Dresden (Germany), ⁹Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, y. - Dresden (Germany), ¹⁰German Center for Neurodegenerative Diseases (DZNE) - Goettingen (Germany), ¹¹Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen y - Goettingn (Germany), ¹²Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro - aveiro (Portugal), ¹³Department of Neurology, University Medical Center, Georg August University, - Goettingen (Germany), ¹⁴German Center for Neurodegenerative Diseases (DZNE) - Magdeburg (Germany), ¹⁵Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University - Magdeburg (Germany), ¹⁶Institute of Cognitive Neuroscience, University College London. - London (United Kingdom), ¹⁷German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany), ¹⁸Department of Neurology, University of Bonn, - Bonn (Germany), ¹⁹German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany), ²⁰Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, - Bonn (Germany), ²¹Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) University of Cologne - Cologne (Germany), ²²Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry, University of Cologne, Medical Faculty, - Cologne (Germany), ²³University Medical Center Rostock, - Rostock (Germany)
- LP071** **A Blueprint for Early Detection of Cognitive Impairment in Primary Care Settings**
Tim Macleod¹, Jim Murray¹, Chantale Bielak², Katherine Selzler¹
¹Davos Alzheimer's Collaborative Health System Preparedness - Wayne (United States), ²Bridgeable - Toronto (Canada)
- LP072** **Implementing cognitive assessment and RetiSpec retinal screening in community-based settings: Enhancing early detection of Alzheimer's disease**
Sharon Cohen¹, Alissa Kurzman^{2,3,4}, Jennifer Giordano², Rozana Naureen², Amelia Hansen¹, Michelle Martinez¹, Mailis Bietenhader², Negar Sohbati⁵, Naeem Abdulla⁶, Colette Cameron⁷, Shmuel Estreicher⁷, Sangeeta Semwel⁷, Catherine Bornbaum²
¹Toronto Memory Program - Toronto (Canada), ²RetiSpec, Inc. - Toronto (Canada), ³University of California, Irvine - Irvine (United States), ⁴Davos Alzheimers Collaborative - Philadelphia (United States), ⁵Victoria Village Optometry - Toronto (Canada), ⁶Summerhill Optometry - Toronto (Canada), ⁷Alzheimer Society of Toronto - Toronto (Canada)
- LP073** **Concurrent Detection of Cognitive Impairment and Aβ PET Status with a Short AI-enabled Digital Cognitive Assessment**
 David Bates¹, Ali Jannati^{1,2}, Karl Thompson¹, Claudio Toro-Serey¹, Joyce Gomes-Osman^{1,3}, Russell Banks¹, Jeff Pobst¹, Connor Higgins¹, John Showalter¹, Sean Tobyn¹, Alvaro Pascual-Leone^{1,2,4}
¹Linus Health, Inc. - Boston (United States), ²Department of Neurology, Harvard Medical School - Boston (United States), ³Department of Neurology, University of Miami Miller School of Medicine - Miami (United States), ⁴Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife - Boston (United States)
-  **LP075** **A pilot test to examine the utility of the Montreal Cognitive Assessment (MoCA) in predicting Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score for eligibility in Alzheimer's Disease (AD) trials**
Elizabeth Sosa¹, Jennifer Mitolo¹, Tara Parnitvithikul¹, Jade Serrano-Sanchez¹, Corinne Karmar¹
¹Irvine Clinical Research - Irvine (United States)
-  **LP076** **Identifying the Severity of Dementia Based on Cognitive Performance and Index of Independence in Basic Activities of Daily Living**
 Duong Huynh¹, Bin Huang¹, Reza Hosseini Ghomi^{1,2}
¹BrainCheck Inc. - Austin (United States), ²Frontier Psychiatry - Billings (United States)
-  **LP077** **Comparing Psychometric Characteristics of a Computerized Cognitive Test (BrainCheck-Assess) against the Montreal Cognitive Assessment (MoCA)**
 Duong Huynh¹, Bin Huang¹, Reza Hosseini Ghomi^{1,2}
¹BrainCheck Inc. - Austin (United States), ²Frontier Psychiatry - Billings (United States)
-  **LP078** **Cognitive effects of a randomized, double-blind, placebo-controlled, 36-week clinical trial of citrus phytochemicals in subjective cognitive decline**
Elena Gatti¹, Giovanni Sgro^{2,3}, Natale Salvatore Bonfiglio⁴, Andrea Geviti⁴, Salvatore Genovese⁵, Serena Fiorito⁵, Lucia Palumbo⁵, Giovanni B. Frisoni⁶, Michela Pievani¹, Francesco Epifano⁵, Samantha Galluzzi¹
¹Laboratory Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia (Italy) ²Molecular Markers Laboratory and ³Clinical Trial Service, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia (Italy) ⁴Service of Statistics, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, (Italy) ⁵Laboratory of Phytochemistry and Chemistry of Natural Products, Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Chieti, (Italy) ⁶University Hospitals and University of Geneva, Geneva (Switzerland)
-  **LP080** **Eco-Exposome and Mild Cognitive Impairment: Linking Environmental and Social Vulnerability Indices to the COG-IT Clinical Trial**
Alisa Adhikari¹, Adaora Nwosu¹, Caroline Hellegers¹, Julia Phillips², Jeffery Petrella³, Davangere Devanand⁴, Murali Doraiswamy¹
¹Neurocognitive Disorders Program, Department of Psychiatry, Duke University School of Medicine - Durham (United States), ²Department of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute - New York City (United States), ³Department of Radiology, Duke University School of Medicine - Durham (United States), ⁴b Department of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute - New York City (United States)

POSTER PRESENTATIONS

- LP121** memTEST, a direct-to-consumer self-administered digital cognitive test SELF completed in under 10 minutes on mobile (Android or iPhone), PC, or tablet to increase clinical trial participation and decrease screen fails for verbal screening tests and fluid biomarkers in Alzheimer's Disease clinical trials
David Watson¹, Sean Stanton², Robert Guilfoyle³, Thomas Mareck³, Brandon Lenox¹
¹K2 Medical Research - Maitland (United States), ²K2 Medical Research - Winter Park (United States), ³Recall Technologies - Orlando (United States)
- LP122** Validating Enhanced Behavioral Measures of Word Recall Based on Underlying Cognitive Processes
Jason Bock^{1,2}, Junko Hara^{1,3}, Dennis Fortier¹, Tushar Mangrola¹, Michael Lee²
¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)
- LP123** ARC-DS: A Digital Cognitive Outcome Measure for Down Syndrome-Associated AD Prevention Trials
Jason Hassenstab¹, Laura Del Hoyo Soriano², Olivia Wagemann³, Asaad Baksh⁴, Andrew Aschenbrenner¹, Beau Ances¹, Juan Fortea², Johannes Levin³, Michael Schöll⁵, Ezequiel Surace⁶, Andre Strydom⁴
¹Washington University in St. Louis - St. Louis (United States), ²Sant Pau Hospital - Barcelona (Spain), ³Ludwig-Maximilian-University - Munich (Germany), ⁴King's College London - London (United Kingdom), ⁵University of Gothenburg - Gothenburg (Sweden), ⁶FLENI Institute - Buenos Aires (Argentina)

THEME: Behavioral disorders and clinical trials

- P138** Effects of brexpiprazole on agitation associated with dementia due to Alzheimer's disease: analysis of pooled efficacy data from two Phase 3 fixed-dose trials by baseline agitation frequency
Jyoti Aggarwal¹, Daniel Lee¹, Nanco Hefting², Dalei Chen¹, Denise Chang¹, Zhen Zhang¹, Maia Miguelez¹, Saloni Behl¹
¹Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ²H. Lundbeck A/S - Valby, Copenhagen (Denmark)
- P139** Effects of brexpiprazole on agitation associated with dementia due to Alzheimer's disease: analysis of pooled response data from two Phase 3 fixed-dose trials
Daniel Lee¹, Jyoti Aggarwal¹, Nanco Hefting², Dalei Chen¹, Denise Chang¹, Saloni Behl¹
¹Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ²H. Lundbeck A/S - Valby, Copenhagen (Denmark)
- P140** Design of ADEPT-2, a phase 3, parallel group study to evaluate KarXT (xanomeline-tropium) as a treatment for psychosis associated with Alzheimer's disease
Minsu Kang¹, Carolyn Watson¹, Jeffrey Cummings², George Grossberg³, Ronald Marcus¹, Paul Yeung¹
¹Karuna Therapeutics - Boston (United States), ²Chambers-Grundy Center for Transformative Neuroscience, University of Nevada, Las Vegas - Las Vegas (United States), ³Department of Psychiatry & Behavioral Neuroscience, Saint Louis University School of Medicine - Saint Louis (United States)
- LP124** A review of meaningful change in agitation behaviors associated with Alzheimer's disease and the potential impact of brexpiprazole
Jyoti Aggarwal¹, Brian Talon², Pedro Such³, Malaak Brubaker¹, David Wang³, Alireza Atri^{4,5,6,7}
¹Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton (United States), ²H. Lundbeck A/S - Deerfield (Denmark), ³H. Lundbeck A/S - Valby, Copenhagen (Denmark), ⁴Banner Sun Health Research Institute - Sun City (United States), ⁵Banner Alzheimer's Institute - Phoenix (United States), ⁶Brigham and Women's Hospital - Boston (United States), ⁷Harvard Medical School - Boston (United States)
- LP125** Longitudinal Effects of Caregiving Burden on Inflammatory Biomarkers in Spousal Caregivers of Individuals with Cognitive Impairments
So Yeon Jeon¹
¹Department of psychiatry, Chungnam National University College of Medicine - Daejeon (Korea, Republic of)
- LP126** Feasibility and acceptability of using technology in caregivers and Alzheimer's disease patients with agitation
H Okhravi¹, A Gupta², S Jain³, K Maly², C Nesbitt², I El Moudden¹, S Alyaan²
¹Eastern Virginia Medical School - Norfolk (United States), ²Old Dominion University - Norfolk (United States), ³Stony Brook University - New York (United States)

THEME: Health economics and clinical trials

- P141** Implications of Treatment Duration and Intensity on the Value of Alzheimer's Treatments
Soeren Matthe¹, Tabasa Ozawa¹, Mark Hanson¹
¹USC - Los Angeles (United States)
- P142** Amyloid PET: The Case for Quantification in Clinical Routine
Phillip Kuo¹, William Jagust², Gill Farrar³
¹U Arizona - Tucson (United States), ²UC Berkeley - Berkeley (United States), ³GE Healthcare - Amersham (United Kingdom)
- P143** Assessing health system capacity for delivery of a disease-modifying therapy for Alzheimer's disease: a multi-country analysis
Ilke Mirik Danaci¹, Valerie Crowell¹, Nathalie Budd², Haakon B Nygaard³
¹F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²F. Hoffmann-La Roche Ltd - Mississauga (Canada), ³Division of Neurology and Djavad Mowafaghian Centre for Brain Health - Vancouver (Canada)

THEME: Epidemiology and clinical trials


- P144 **State Department of Motor Vehicles clinician reporting mandates of dementia diagnoses: Evidence for risks and benefits**
Hankyung Jun¹, Ying Liu², Emily Chen², Andrew Becker², Soeren Mattke²
¹Harvard Medical School - Boston (United States), ²University of Southern California - Los Angeles (United States)
- P145 **Age-specific relative comorbidity burden of mild cognitive impairment: A US database study**
Gang Li¹, Nicola Toschi², Viswanath Devanarayan¹, Richard Batrla¹, Tommaso Boccatto², Min Cho¹, Matteo Ferrante², Feride Frech¹, James Galvin³, David Henley⁴, Soeren Mattke⁵, Susan De Santi¹, Harald Hampel¹
¹Eisai Inc - Nutley (United States), ²University of Rome Tor Vergata - Rome (Italy), ³University of Miami - Miami (United States), ⁴Janssen Research & Development - New Brunswick (United States), ⁵University of Southern California - Los Angeles (United States)
- P146 **Comorbidities Occurring Before and After Diagnosis of Mild Cognitive Impairment or Alzheimer's Disease: A Large US Nationwide Electronic Health Record Cohort Study**
Lisa Vinikoor-Imler¹, Olga Sanchez-Solino¹, Emma Xiaomeng Yue¹, Isabella Boroje¹
¹AbbVie Inc - Chicago (United States)
- P147 **Biomarker and clinical correlations for amyloid targeting monoclonal antibody (mAb) treatment responses**
Jonathan Wagg¹, Nicolas Fournier¹, Garance Lucken¹, Clarisse Schumer², Olivier Sol¹, Julian Gray¹, Marija Vukicevic¹, Marie Kosco-Vilbois¹, Andrea Pfeifer¹, Johannes Streffer¹
¹AC Immune SA - Lausanne (Switzerland), ²EPFL - Lausanne (Switzerland)
- P148 **High prevalence of amyloid cerebral pathology in older adults with cognitive frailty - an indication for anti-amyloid therapies?**
Sandrine Sourdet¹, Gaëlle Soriano¹, Bruno Vellas¹
¹Gerontopôle - Toulouse (France)
-  P149 **Acculturation-related characteristics associated with research attitudes among underrepresented populations recruited to an Alzheimer's disease preclinical trial**
Christian Salazar¹, Hye-Won Shin¹, Melanie Tallakson¹, Edwin Duran¹, Russ Eunji¹, Maria Corona¹, Romina Romero¹
¹UC Irvine Institute for Memory Impairments and Neurological Disorders - Irvine (United States)
- P150 **Sildenafil is a candidate drug for Alzheimer's disease: Real-world patient data observation**
Cheng Feixiong¹, Zhang Pengyue², Jeffrey Cummings³
¹Cleveland Clinic - Cleveland (United States), ²Indiana University - Bloomington (United States), ³University of Nevada Las Vegas - Las Vegas (United States)
- LP081 **Bridging the Gap: Enhancing Representation in Alzheimer's Clinical Trials Through Strategic Collaboration with Primary Care Clinics in Diverse Communities**
Brina Quaning¹, Santiago Santeli², Sandra Carmona Torres², Lucy Lenox², Bryce Warner², Sheila Baez-Torres²
¹Metro Health Inc - Orlando (United States), ²K2 Medical Research - Orlando (United States)
- LP082 **Predictors of Response Rate to a Mailed Invitation to Participate in a Dementia Prevention Lifestyle Intervention Trial (U.S. POINTER): Houston Site Experience**
Valory Pavlik¹, Melissa Yu¹, Hannah Shields¹, Ashley Alexander², Rose Trevino-Whitaker², John Valenta², Richard ElPein³, Ann Marie McDonald³
¹Baylor College Of Medicine - Houston (United States), ²Kelsey Research Foundation - Houston (United States), ³Alzheimer's Association - Houston (United States)
-  LP083 **Alzheimer's disease linkage to evidence (AD-LINE) study: An analysis of concordance between clinical diagnosis and evidence of AD diagnosis in real-world US claims data**
 Howard Fillit^{1,2}, Sheila Seleri Assunção³, Chris Wallick³, Ibrahim M. Abbass³, Carmen Ng³, Tu My To³, Karina Raimundo³, Thomas Majda³, Desilu Glazebrook³, Oleg V. Tcheremissine⁴
¹Alzheimer's Drug Discovery Foundation - New York City (United States), ²Departments of Geriatric Medicine, Medicine, and Neuroscience, Icahn School of Medicine at Mount Sinai - New York City (United States), ³Genentech, Inc., a member of the Roche Group - South San Francisco (United States), ⁴Department of Psychiatry, Atrium Health Behavioral Health Charlotte - Charlotte (United States)
- LP127 **Characteristics of adults with incident cognitive impairment in a population-based study of cognitive aging**
Khaled Ghoniem¹, Jeremiah A. Aakre², Anna M. Castillo², Mohamed Elminawy¹, Emma A. Brauer¹, Prashanthi Vemuri³, Clifford R. Jack Jr.³, Jonathan Graff-Radford¹, David S. Knopman¹, Ronald C. Petersen¹, Maria Vassilaki¹
¹Department of Neurology, Mayo Clinic - Rochester (United States), ²Department of Quantitative Health Sciences, Mayo Clinic - Rochester (United States), ³Department of Radiology, Mayo Clinic - Rochester (United States)
- LP128 **Study Partner Effect on Retention in Alzheimer's Disease Trials**
Michelle Nuño¹, Daniel Gillen², Joshua Grill²
¹University of Southern California - Los Angeles (United States), ²University of California, Irvine - Irvine (United States)

POSTER PRESENTATIONS

THEME: Animal model

- P151** **Deciphering the mechanisms of action of cognitive gain using the multidomain lifestyle intervention protocol – from human RCTs to mice**
Vilma Alanko ^{1,2}, Francesca Erolti ², Alina Solomon ^{3,4}, Krister Håkansson ¹, Tiia Ngandu ⁵, Tobias Hartmann ^{6,7}, Per Nilsson ², Miia Kivipelto ^{1,4,8}, Silvia Maioli ², [Anna Matton](#) ^{1,2,4}
¹Division of Clinical Geriatrics, Department of NVS, Karolinska Institutet - Solna (Sweden), ²Division of Neurogeriatrics, Department of NVS, Karolinska Institutet - Solna (Sweden), ³Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), ⁴Ageing Epidemiology (AGE) Research Unit, Imperial College London - London (United Kingdom), ⁵Population Health Unit, Finnish Institute for Health and Welfare - Helsinki (Finland), ⁶Deutsches Institut für Demenz Prävention (DIDP), Saarland University - Homburg (Germany), ⁷Department of Experimental Neurology, Medical Faculty, Saarland University - Homburg (Germany), ⁸Theme Inflammation and Aging, Karolinska University Hospital - Solna (Sweden)
- P152** **Subcellular and secretory effects of the App^{MLF} knock-in in mice neurons**
[Sophia Schediin-Weiss](#) ¹, Yang Yu ¹, Robin Z. Zhou ¹, Lars O. Tjernberg ¹
¹Karolinska Institutet - Solna (Sweden)
- LP084** **TREM2 Agonism Affects Human Microglia Response in the Presence of Amyloid Pathology In Vivo**
[Peter Flagstad](#) ¹, Ivana Geric ^{1,2,3}, Manuela Polydoro ¹, Leen Wolfs ^{2,3}, Anke Misbaer ^{1,2,3}, Arya Nair ^{2,3}, Laura Sans ¹, Maria DaLPy ¹, Jin Zheng ¹, Tina Sommer Bisgaard ¹, Lars Christian Roenn ¹, Rita Balice-Gordon ¹, Bart De Strooper ^{2,3,4}, Niels Plath ¹
¹Muna Therapeutics - Copenhagen (Denmark), ²Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB) - Leuven (Belgium), ³Department of Neurosciences and Leuven Brain Institute, KU Leuven - Leuven (Belgium), ⁴UK Dementia Research Institute at UCL, University College London - London (United Kingdom)
- LP085** **KIT-13, an Innovative Plasmalogen Derivative, Improved Memory and Cognition through Suppression of Neuroinflammation in Murine Models**
[Md Shamim Hossain](#) ¹, Shiro Mawatari ¹, Masanori Honsho ², Takehiko Fujino ³
¹Institute of Rheological Functions of Food - Fukuoka (Japan), ²Kyushu University - Fukuoka (Japan), ³Neurocores - Boston (United States)
- LP086** **Protective Effects of New Combination Drug FPT-03 in Oxidative Damages and Cognitive Impairments against Traumatic Brain Injury**
[William Chao](#) ¹, Bert Chen ¹, Chia-Yi Tseng ²
¹Future PharmTech - Taipei (Taiwan, Republic of China), ²Chung Yuan Christian University - Taoyuan (Taiwan, Republic of China)
-  **LP087** **Nonfibrillar Dutch mutant amyloid beta (Aβ) aggregates (oligomers) revealed by anti-prefibrillar oligomer antibody A11 and FITC-peptide imaging are associated with aging-related synaptic dysfunction but cause no detectable inflammation**
[Sam Gandy](#) ¹, Emilie Castranio ¹, Merina Varghese ¹, Elentina Argyrousi ², Kuldeep Tripathi ³, Charles Glabe ⁴, Efrat Levy ⁵, Minghui Wang ¹, Bin Zhang ¹, William Lubell ⁶, Brigitte Guerin ⁷, Shai Rahimpour ⁸, Dara Dickstein ⁹, Ottavio Arancio ², Michelle Ehrlich ¹
¹Icahn School of Medicine - New York (United States), ²Columbia U - New York (United States), ³Bar Ilan U - Raman Gat (Israel), ⁴U Calif Irvine - Irvine (United States), ⁵NYU & NKI - New York (United States), ⁶U Montreal - Montreal (Canada), ⁷U Sherbrooke - Sherbrooke (Canada), ⁸Bar Ilan U - Raman Gat (Canada), ⁹Uniformed Health Sci U - Bethesda (United States)
-  **LP088** **Humanized model to study the role of Kv1.3 blockade on microglia in neuroinflammation**
Ivana Geric ¹, Lucas Baltussen ², Leen Wolfs ², Anke Misbaer ¹, Negin Afrang ², Laura Sans ¹, Maria DaLPy ¹, Anja Koustrup ¹, Dorota Kuczek ¹, Jorge Valadas ¹, Lars Christian Roenn ¹, Marianne Terndrup Pedersen ¹, Rita Balice-Gordon ¹, Bart De Strooper ^{2,3,4}, [Niels Plath](#) ¹
¹Muna Therapeutics - Copenhagen (Denmark), ²Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB) - Leuven (Belgium), ³UK Dementia Research Institute at UCL - London (United Kingdom), ⁴Department of Neurosciences and Leuven Brain Institute, KU Leuven - Leuven (Belgium)
-  **LP089** **Impact of 'Masked' 40 Hz Light Therapy on Cognitive Decline and Associated Neuropathology in a Mouse Model of Alzheimer's Disease**
[Madison Browne](#) ¹, Olive Curreri ¹, Stephanie Ancheta ¹, Lucy Jiwu ¹, Stephanie Wu ¹, Lynn Yang ¹, Yuanyuan Yao ¹, Marcus Carstensen ^{2,3}, Mai Nguyen ², Daniela Kaufer ¹, Lance Kriegsfeld ¹
¹University of California, Berkeley - Berkeley (United States), ²OptoCeutics ApS - Copenhagen (Denmark), ³Technical University of Denmark - Lyngby (Denmark)

THEME: New therapies and clinical trials

-  **P153** **Impact of adherence on cognitive outcomes in a pilot study of the Cogstim model**
[Raymond L Ownby](#) ¹
¹Nova Southeastern University - Fort Lauderdale (United States)
- P154** **Pivotal trial of low-intensity pulsed ultrasound therapy for early stage of Alzheimer's disease (LIPUS-AD) –Rationale and design-**
[Hiroaki Shimokawa](#) ^{1,2}, Masanori Akishita ³, Masafumi Ihara ⁴, Satoshi Teramukai ⁵, Aiko Ishiki ⁶, Yoji Nagai ⁷, Hajimu Kato ², Masanori Fukushima ⁸
¹International University of Health and Welfare - Narita (Japan), ²Sound Wave Innovation Inc. - Tokyo (Japan), ³University of Tokyo - Tokyo (Japan), ⁴National Cerebrovascular and Cardiovascular Center - Suita (Japan), ⁵National Cerebrovascular and Cardiovascular Center - Kyoto (Japan), ⁶Tohoku Medical and Pharmaceutical University - Sendai (Japan), ⁷Kyoto University - Kyoto (Japan), ⁸Learning Health Society Institute - Nagoya (Japan)
- P155** **Masupirdine (A Pure 5-HT6 Receptor Antagonist) for the Treatment of Agitation in Patients with Dementia of Alzheimer's Type - Rationale and Phase-3 Study Design**
Ramakrishna Nirogi ¹, Jyothsna Ravula ¹, Satish Jetta ¹, Vinod Kumar Goyal ¹, [Pradeep Jayarajan](#) ¹, Vijay Benade ¹, Anil Shinde ¹, Santosh Kumar Pandey ¹, Ramkumar Subramanian ¹, Abdul Rasheed Mohammed ¹, Venkat Jasti ¹
¹Suven Life Sciences Ltd - Hyderabad (India)

POSTER PRESENTATIONS

Poster presentations presented [remotely](#) are indicated with this icon: 

- P157 **Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate**
[Linda Van Eldik](#)¹, [Wendy Ziai](#)², [Lauren Sansing](#)³, [Daniel Hanley](#)²
¹University of Kentucky - Lexington (United States), ²Johns Hopkins University - Baltimore (United States), ³Yale University - New Haven (United States)
- P158 **Treatment of early symptomatic Alzheimer's disease with nasal Protollin to activate monocytes and clear amyloid beta**
[Panayota Kolypetri](#)¹, [Patrick Da Silva](#)¹, [Lei Liu](#)¹, [Christian D. Gauthier](#)¹, [Taylor J. Saraceno](#)¹, [Tarun Singhal](#)¹, [Seth A. Gale](#)¹, [Tanuja Chitnis](#)¹, [Dennis J. Selkoe](#)¹, [Howard L. Weiner](#)¹
¹Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)
- LP090 **The purely thermodynamic anti-prionic mode of action for the treatment of neurodegenerative diseases**
[Dieter WillPold](#)¹
¹Forschungszentrum Jülich - Jülich (Germany)
- LP091 **Rationale for a trial in type 2 diabetes and/or coronary artery disease: Combined intervention with exercise and a soluble epoxide hydrolase inhibitor**
[Myuri Ruthirakuhan](#)^{1,2}, [Natasha Anita](#)^{1,2,3}, [Jennifer S. Rabin](#)^{2,3,4}, [Maged Goubran](#)², [Nathan Herrmann](#)², [Paul I. Oh](#)⁵, [Ameer Y. Taha](#)⁶, [Sandra E. Black](#)^{2,5}, [Carmela Tartaglia](#)⁷, [Ana C. Andreazza](#)¹, [Hugo Cogo-Moreira](#)⁸, [Jodi Edwards](#)⁹, [Krista Lancot](#)^{1,2,3,10}, [Walter Swardfager](#)^{1,2,3}
¹Department of Pharmacology & Toxicology - University of Toronto - Toronto (Canada), ²Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute - Toronto (Canada), ³KITE Research Institute, Toronto Rehabilitation Institute-University Health Network - Toronto (Canada), ⁴Rehabilitation Sciences Institute, Temerty Faculty of Medicine, University of Toronto - Toronto (Canada), ⁵Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto - Toronto (Canada), ⁶Department of Food Science and Technology, College of Agriculture and Environmental Sciences, University of California, Davis; West Coast Metabolomics Center, Genome Center, University of California - Davis; Center for Neuroscience, One Shields Avenue, University of California - Davis, Ca (United States), ⁷Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto - Toronto (Canada), ⁸Department of Education, ICT and Learning, Østfold University College - Østfold (Norway), ⁹School of Epidemiology and Public Health-University of Ottawa - Ottawa (Canada), ¹⁰Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto - Toronto (Canada)
- LP092 **Personalized hippocampal network-targeted stimulation for Alzheimer's disease: A randomized controlled trial**
[Young Hee Jung](#)¹, [Hyemin Jang](#)², [Sungbeen Park](#)³, [Hee Jin Kim](#)², [Sang Won Seo](#)², [Guk Bae Kim](#)⁴, [Duk Lyul Na](#)⁵
¹Myongji Hospital, College of Medicine, Hanyang University - Goyang (Korea, Republic of), ²Samsung Medical Center - Seoul (Korea, Republic of), ³Hanyang University - Seoul (Korea, Republic of), ⁴anymed - Seoul (Korea, Republic of), ⁵Sungkyunkwan University - Seoul (Korea, Republic of)
- LP093 **Efficacy and Safety Of AXS-05 in Agitation Associated With Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial**
[Jeffrey Cummings](#)¹, [George Grossberg](#)², [Candace Andersson](#)³, [Graham Eglit](#)³, [Caroline Streicher](#)³, [Herriot Tabuteau](#)³
¹University of Nevada, Las Vegas - Las Vegas, Nv (United States), ²Saint Louis University School of Medicine - St. Louis, Mo (United States), ³Axsome Therapeutics - New York, Ny (United States)
-  LP094 **A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Escalating Single and Multiple Doses of DGX-001 in Healthy Volunteers Followed by a Stress Exposure Resilience Panel (SERP)**
[Tom Polasek](#)¹, [Titus Plattel](#)², [Richard Kim](#)², [Steve Smith](#)², [Igor Grachev](#)², [Neil Schwartz](#)², [Dirk Smith](#)²
¹Monash University - Melbourne (Australia), ²Viage - Palo Alto (United States)
-  LP095 **NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer's disease shows neuroprotective and neurorestorative effects**
[Pontus Forsell](#)^{1,2}, [Veronica Lidell](#)^{1,2}, [Azita Rasti](#)^{1,2}, [Gunnar Nordvall](#)^{1,2}, [Johan Sandin](#)^{1,2}, [Martin Jönsson](#)^{1,2}
¹AlzeCure Pharma AB, Hälsovägen 7, Sweden - Huddinge (Sweden), ²Division of Neuroscience, Care and Society, Karolinska Institutet, Sweden - Solna (Sweden)
-  LP096 **Phase 1 SAD/MAD data and Phase 2 study design for LHP588, a second-generation gingipain inhibitor for the treatment of P. gingivalis-positive Alzheimer's dementia**
[Michael Detke](#)¹, [Marwan Sabbagh](#)², [Joanna Bolger](#)¹, [Jianhong Wang](#)¹, [Mark Ryder](#)³, [Suzanne Hendrix](#)⁴, [Sam Dickson](#)⁴, [Craig Mallinckrodt](#)⁴, [Leslie Holsinger](#)¹, [Casey Lynch](#)¹, [Stephen Dominy](#)¹
¹Lighthouse Pharmaceuticals - San Francisco (United States), ²Barrow Neurological Institute - Phoenix (United States), ³University of California, San Francisco, CA - San Francisco (United States), ⁴Pentara Corp - Millcreek (United States)
-  LP097 **Alzheimer's Disease Research Recruitment in a World with Disease Modifying Treatments on Market**
[Ira Goodman](#)¹, [Daniel Gautieri](#)¹, [Erin Beck](#)¹, [Michael Stalder](#)¹
¹SiteRx - New York (United States)
- LP129 **Treatment of Alzheimer's Disease Subjects With Expanded Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity — Final Report of a Phase I Dose Escalation Study**
[Clemente Humberto Zuniga Gil](#)¹, [Blanca Isaura Acosta Gallo](#)¹, [Rufino Menchaca Diaz](#)¹, [Cesar Alejandro Amescua](#)¹, [Sean Hong](#)², [Lucia Hui](#)², [Hank Lee](#)², [Juan Mata](#)², [Paul Y. Chang](#)², [Katia Betito](#)², [Paul Y. Song](#)²
¹Hospital Angeles - Tijuana (Mexico), ²NKGen Biotech - Santa Ana (United States)
- LP130 **Anti-Abeta liposomal vaccine, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies**
[Emma Fiorini](#)¹, [Chiara Babolin](#)¹, [Rakel Carpintero](#)¹, [Stefania Rigotti](#)¹, [Stefanie Siegert](#)¹, [Catherine Morici](#)¹, [Maelle Verardo](#)¹, [Jonathan Wagg](#)¹, [Piergiorgio Donati](#)¹, [Saskia Delpretti](#)¹, [Johannes Streffer](#)^{1,2}, [Andrea Pfeifer](#)¹, [Marie Kosco-Vilbois](#)¹, [Marija Vukicevic](#)¹
¹AC Immune SA - Lausanne (Switzerland), ²University of Antwerp - Antwerp (Belgium)

POSTER PRESENTATIONS

THEME: Proof of concept/Translational research for Alzheimer Drug Development interventions

- P159 **D-peptide-magnetic nanoparticles disaggregate tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease**
Ke Hou¹, Hope Pan¹, David Eisenberg¹
¹*UCLA - Los Angeles (United States)*
- P160 **Structural dynamics of amyloid- β protofibrils and action of lecanemab as observed by high-speed atomic force microscopy**
Kenjiro Ono¹, Takahiro Nakayama², Mayumi Tsuji³, Kenichi Umeda², Tatsunori Oguchi³, Hiroki Konno², Moeko Shinohara¹, Yuji Kiuchi³, Noriyuki Koderu², David B. Teplow⁴
¹*Kanazawa University Graduate School of Medical Sciences - Kanazawa (Japan)*, ²*Nano Life Science Institute, Kanazawa University - Kanazawa (Japan)*, ³*Showa University School of Medicine - Tokyo (Japan)*, ⁴*David Geffen School of Medicine at UCLA - Los Angeles (United States)*
- P161 **APOE-Targeted Epigenome Therapy for Alzheimer's Disease: Pre-Clinical Studies**
Ornit Chiba-Falek^{1,2}, Boris Kantor^{1,2}
¹*Duke University - Durham (United States)*, ²*CLAIRGene, LLC - Durham (United States)*
-  P162 **A Possible Pathogenic PSEN2 Glu56Ser Mutation in a Korean Patient with Early-Onset Alzheimer's Disease**
Da-Eun Jeong¹, Min Ju Kang¹
¹*Department of Neurology, Veterans Health Service Medical Center - Seoul (Korea, Republic of)*
- P163 **Effect of spectral binning in x-ray scattering method for non-invasively characterizing amyloids**
Eshan Dahal¹, Sabri Amer¹, Karthika Suresh¹, Olivia Sandvold², Peter Noël², Aldo Badano¹
¹*U.S. Food and Drug Administration - Silver Spring (United States)*, ²*University of Pennsylvania - Philadelphia (United States)*
- P164 **Novel brain shuttle platform for precision delivery of Alzheimer's disease therapeutics**
Liqun Wang¹, João Santos², Amy England¹, Yife Lu¹, Amanda Graveline¹, Melinda Sanchez¹, Teresa Barata², Daniela Teixeira², Donald Ingber¹, James Gorman¹
¹*Wyss Institute at Harvard University - Boston (United States)*, ²*FairJourney Biologics - Porto (Portugal)*
- P165 **Equilibrative nucleoside transporter 1 (ENT1) as a promising therapeutic target to rescue pathological features and alleviate cognitive impairment in Alzheimer's disease**
Chien-Yu Lin^{1,2}, Ching-Pang Chang^{1,2}, Kuo-Chen Wu^{2,3}, Ching-Wen Wu^{1,2}, Chun-Jung Lin^{2,3}, Yijiang Chern^{1,2}
¹*Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China)*, ²*Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China)*, ³*School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China)*
- P166 **Study of novel copper and zinc binding analogue of GMP-1 in Tg4510 tauopathy mouse model**
Bengt Winblad¹, Zhe Zhao¹, Pavel Pavlov¹
¹*Karolinska Institutet - Solna (Sweden)*
- P167 **Novel small molecule poly-disaggregator therapeutics for AD, ALS and FTD reduce TDP-43 oligomerization, aggregation, and pathology**
Marcela Kokes¹, Vidhu Mathur¹, Eric Shao¹, Shruti Arya¹, Catherine Planey¹
¹*Acelot - Palo Alto (United States)*
- P168 **Differences in Glutaminyl Cyclase protein levels in Mild Cognitive Impairment subjects**
Xavier Morato¹, Amanda Cano¹, Sergi Valero¹, Raul Nuñez¹, Raquel Puerta¹, Jose Antonio Allué¹, Leticia Sarasa¹, Agustín Ruiz¹, Mercè Boada¹
¹*FUNDACIO ACE - Barcelona (Spain)*
- P169 **White matter hyperintensity accumulation is related to cerebral amyloid angiopathy and neurodegeneration in autosomal dominant and sporadic AD**
Zahra Shirzadi¹, Stephanie Schultz¹, Wai-Ying Yau¹, Nelly Friedrichsen², Kejal Kantarci³, Gregory Preboske³, Clifford Jack Jr³, Brian Gordon², Eric Mcdade², Tammie Benzinger², Randall Bateman², Steven Greenberg¹, Reisa Sperling¹, Aaron Schultz¹, Jasmeer Chhatwal¹
¹*Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)*, ²*Washington University in St. Louis School of Medicine - St. Louis (United States)*, ³*Mayo Clinic, Radiology - Rochester (United States)*
- P170 **Systematic in silico analysis of clinically tested drugs for reducing amyloid beta plaque accumulation in Alzheimer's disease**
Sarah Head¹, Raibatak Das¹, Brian Campbell², Dan Zweifel², John Burke¹, Joshua Apgar¹, Fei Hua¹
¹*Applied BioMath - Concord, Massachusetts (United States)*, ²*Prothema Biosciences Inc. - South San Francisco, California (United States)*
- P171 **In Silico Simulation of Dementia-Alzheimer-Syndrome: Application of hybrid computing approach to the study of emergent behavior**
Ara Khachaturian¹, Zaven Khachaturian¹, Jeanmarie Bouteiller², Eva Troppová³, Vaclav Snášel⁴, Vit Vondrák⁴, Jiri Damborský⁵, Stanislav Mazurenko⁵, Josef Šivic³, Vit Dočkal³
¹*Campaign to Prevent Alzheimer's Disease - Rockville (United States)*, ²*University of Southern California - Los Angeles (United States)*, ³*Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University - Prague (Czech Republic)*, ⁴*Technical University of Ostrava - Ostrava (Czech Republic)*, ⁵*International Clinical Research Center of St. Anne's University Hospital - Brno (Czech Republic)*
- P172 **Neuroprotective and mnesic-improving effects of Fluoroethylnormemantine (FENM) in the AB25-35 mouse model of Alzheimer's disease**
Allison Carles¹, Aline Freysson², Florent Perin-Dureau², Gilles Rubinstenn², Tangui Maurice¹
¹*MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France*, ²*ReST Therapeutics - Paris (France)*

- P173** **Nanolithium has a dual potential in Alzheimer's disease: to treat Neuropsychiatric Symptoms and modify disease course**
 Maria Eugenia Soto-Martin ¹, [Solene Guilliot](#) ², Pierre-Jean Ousset ¹, Karim Bennys ³, Claire Paquet ⁴, Jacques Touchon ⁵, Edward N Wilson ⁶
¹Alzheimer's disease Memory Research & Clinical center, Department of Geriatrics, Gerontopole, Hôpital Lagrave - Toulouse (France), ²Medesis Pharma - Baillargues (France), ³Alzheimer's disease Memory Research & Clinical center, Department of Neurology, University Hospital Gui de Chauliac - Montpellier (France), ⁴Cognitive Neurology Center, Lariboisière Fernand-Widal Hospital APHP Université de Paris Cité - Paris (France), ⁵University of Montpellier - Montpellier (France), ⁶Neurology & Neurological Sciences, Stanford School of Medicine - Stanford (United States)
- P174** **Advancing Diverse Recruitment by Assessing Facilitators and Barriers to Participation in Alzheimer's and Dementia-Related Research**
[John Lucas](#) ¹, Shawna Green ¹, Maisha Robinson ¹, Aaron Spaulding ¹
¹Mayo Clinic - Jacksonville (United States)
- P175** **Fosgonimeton, a small-molecule positive modulator of the HGF/MET system, attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease**
 Sherif Reda ¹, Sharay Setti ¹, Andrée-Anne Berthiaume ¹, Wei Wu ¹, Jewel Johnston ¹, [Robert Taylor](#) ¹, Kevin Church ¹
¹Athira Pharma, Inc. - Bothell (United States)
- P176** **Designed peptide targeting α -sheet Amyloid- β oligomers decreases toxic oligomer burden and improves behavior in AD mouse models**
[Carolyn Tallon](#) ¹, Chandresh Gajera ¹, Jeff Posakony ¹, GiLPert Block ¹, Valerie Daggett ¹
¹AltPep Corporation - Seattle (United States)
- P177** **Unraveling the therapeutic potential of novel hyaluronic acid estradiol conjugate ND108E in Alzheimer's Disease: Mechanistic insights and future directions**
[Chia-Lung Hou](#) ¹, Szu-Yuan (viola) Lee ¹, Jia-Chi Wang ¹, Ting-An Chen ¹, Kai-Ting Chang ¹, Mu-Hsuan Chen ², Hsiao-Chun Lin ², Tzu Chao ², Tsyrr-Jiuan Wang ³, Jeng-Rung Chen ²
¹Holy Stone HealthCare - Taipei (Taiwan, Republic of China), ²National Chung-Hsing University - Taichung (Taiwan, Republic of China), ³National Taichung University of Science and Technology - Taichung (Taiwan, Republic of China)
- P178** **Structural and biochemical similarities of protofibrils and plaque fibrils: implications for anti-amyloid immunotherapy**
[Andrew Stern](#) ¹, Yang Yang ², Shanxue Jin ¹, Keitaro Yamashita ², Angela Meunier ¹, Wen Liu ¹, Yuqi Cai ¹, Maria Ericsson ³, Lei Liu ¹, Michel Goedert ², Sjors Scheres ², Dennis Selkoe ¹
¹Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston (United States), ²MRC Laboratory for Molecular Biology - Cambridge (United Kingdom), ³Harvard Medical School - Boston (United States)
- LP098** **Human specific α 7nAChR-dependent adaptation to mechanical properties of the extracellular environment**
 Ivanna Ihnatovych ¹, Ryu P. Dorn ¹, Erik Nimmer ¹, Yuna Heo ¹, Yongho Bae ¹, [Kinga Szigeti](#) ¹
¹University at Buffalo - Buffalo (United States)
- LP099** **Mechanistic insights into the translational gap for cholinergic therapies in Alzheimer's Disease**
[Kinga Szigeti](#) ¹, Ivanna Ihnatovych ¹, Nicolás Rosas ^{2,1}, Ryu P. Dorn ¹, Emily Notari ¹, Ziquiang Chen ¹, Eduardo Cortes Gomez ³, Muye He ¹, Megan Del Regno ¹, David A. Bennett ⁴, Arnd Pralle ¹, Yongho Bae ¹, Jianmin Wang ³, Gregory Wilding ¹
¹University at Buffalo - Buffalo (United States), ²Universidad Nacional de San Martin - Buenos Aires (Argentina), ³Roswell Park Comprehensive Cancer Center - Buffalo (United States), ⁴Rush Alzheimer's Disease Center - Chicago (United States)
- LP100** **Human restricted CHRFB7A gene may enhance brain efficiency**
[Kinga Szigeti](#) ¹, Ryu P. Dorn ¹, Megan Del Regno ¹, Jakimovski Dejan ², Niels Bergsland ², Murali Ramanathan ¹, Michael G. Dwyer ², Ralph H. Benedict ¹, Robert Zivadinov ¹
¹University at Buffalo - Buffalo (United States), ²Buffalo Neuroimaging Analysis Center - Buffalo (United States)
- LP101** **Combined E2 and Christchurch Gain-of-Function Variants of the Human APOE Gene Delivered by AAVrh.10 Effectively Suppresses Both Amyloid and Tau Pathology in the CNS of Murine Models of APOE4 Homozygous Alzheimer's Disease**
 Cancer Günaydin ¹, Dolan Sondhi ¹, Stephen Kaminsky ¹, Hailey Lephart ¹, [Philip Leopold](#) ¹, Richie Khanna ², Ronald Crystal ¹
¹Weill Cornell Medical College - New York (United States), ²LEXEO Therapeutics - New York (United States)
- LP102** **New Approach to Alzheimer's Disease - Novel Chimeric GAS6 Fusion Protein**
[Soomin Ji](#) ¹, Haejung Han ¹, Jaekeun Lee ¹, Sanghoon Park ¹, Won-Suk Chung ^{1,2}, Chan Hyuk Kim ^{1,2}
¹Illim Therapeutics, Inc. - Seoul (Korea, Republic of), ²Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST) - Daejeon (Korea, Republic of)
- LP104** **Microglia-Specific APOE-Targeted Epigenome Therapy for Alzheimer's Disease**
[Ornit Chiba-Falek](#) ¹, Elena Korsakova ², Kantor Boris ¹
¹Duke University - Durham (United States), ²CLAIRGene - Durham (United States)
- LP105** **ABvac40 induces anti-A β -40 plasma specific antibodies that bind with A β vascular deposits in brain slices from humans with cerebral amyloid angiopathy**
 María Montañes ¹, Jesús Canudas ¹, Ignacio Martinez ¹, Ana María Lacosta ¹, María Pascual-Lucas ¹, [Jose Terencio](#) ^{2,1}
¹Araclon Biotech-Grifols - Zaragoza (Spain), ²Grifols - Barcelona (Spain)

POSTER PRESENTATIONS

-  **LP106 Centiloid scale expression using Neurophet SCALE PET with diverse tracer comparison**
Choe Yeong Sim¹, Lee Min-Woo¹, Kim Hajin¹, Lee Jiyeon¹, Moon Youngjoon¹, Lee Minho¹, Kim Donghyeon¹, Kim Regina Ey¹
¹Research Institute, Neurophet Inc. - Seoul (Korea, Republic of)
-  **LP107 Simufilam's primary mechanism of action confirmed by time-resolved FRET**
Erika Cecon¹, Julie Dam¹, Lindsay Burns², Ralf Jockers¹
¹. Université Paris Cité, Institut Cochin, INSERM, CNRS - Paris (France), ²Cassava Sciences, Inc. - Austin, Tx (United States)
-  **LP108 Prediction of global standardized uptake value ratio and amyloid status with both T1-weighted and T2-FLAIR image using deep learning**
Min-Woo Lee¹, Hyeon Sik Yang¹, Hye Weon Kim¹, Yeong Sim Choe¹, Ji Min Kang¹, Soo Hyun Jeon¹, Young Joon Moon¹, Dong Hyeon Kim¹, Min Ho Lee¹, Dong Woo Kang², So Yeon Jeon³, Sang Joon Son⁴, Young-Min Lee⁵, Regina Kim¹, Hyun Kook Lim⁶
¹Research Institute, Neurophet Inc. - Seoul (Korea, Republic of), ²Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, Chungnam National University Hospital - Daejeon (Korea, Republic of), ⁴Department of Psychiatry, Ajou University School of Medicine - Suwon (Korea, Republic of), ⁵Department of Psychiatry, Medical Research Institute, Pusan National University Hospital - Busan (Korea, Republic of), ⁶Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)
- THEME: Digital health/E-trials**
- P179 Development of a mild cognitive impairment risk prediction model using electronic health record data**
Gang Li¹, Viswanath Devanarayan¹, Rachel Halpern², Richard Batrla¹, Susan De Santi¹, Feride Frech¹, Jo Vandercappellen¹, Ara S. Khachaturian³, Richard Crislip⁴, Soeren Matkke⁵, Harald Hampel¹
¹Eisai - Nutley (United States), ²Optum - Eden Prairie (United States), ³Prevent Alzheimer's Disease 2020, Inc. - Rockville (United States), ⁴OptumCare - Phoenix (United States), ⁵University of Southern California - Los Angeles (United States)
- P180 Validating a novel digital cognitive platform: sensitivity to change following an alcohol challenge**
John Dyer¹, Florentine Barbey², Md Nurul Islam², Judith Jaeger^{3,4}, Brian Murphy², Niamh Kennedy⁵
¹Cumulus Neuroscience - Belfast (United Kingdom), ²Cumulus Neuroscience - Dublin (Ireland), ³CognitionMetrics - Stamford, Ct (United States), ⁴Albert Einstein College of Medicine - Bronx, Ny (United States), ⁵University of Ulster - Coleraine (United Kingdom)
- P181 The effects of home-based, semi-computerized cognitive training on cognitive function in community dwelling older adults**
Geon Ha Kim¹, Bori R. Kim², Haeun Kim³, Jee Hyang Jeong⁴
¹Department of Neurology, Ewha Womans University, College of Medicine - Seoul (Korea, Republic of), ²Ewha Medical Research, Institute Ewha Womans University - Seoul (Korea, Republic of), ³Department of Artificial Intelligence Convergence, Ewha Womans University - Seoul (Korea, Republic of), ⁴Ewha Womans University - Seoul (Korea, Republic of)
-  **P182 Comparing the Effects of Combined Cognitive and Functional Skills Training to Skills Training Alone: Burst Training Increases Training Gains without Increasing Drop-outs**
Philip Harvey¹, Peter Kallestrup², Sara Czaja³
¹University of Miami Miller School of Medicine - Miami (United States), ²i-Function - Miami (United States), ³Weill Cornell Medical Center - New York (United States)
- P183 A real-world, longitudinal observational study in patients with Alzheimer's Disease dementia and healthy controls, using frequent repeated digital measurements performed at-home on the Cumulus Platform: a preliminary report**
Alison Buick¹, Azar Alexander-Sefre¹, Shannon Diggin¹, John Dyer¹, Brian Murphy², Hugh Nolan², Laura Rueda-Delgado², James Rowe³, Kinan Muhammed⁴
¹Cumulus Neuroscience Ltd - Belfast (United Kingdom), ²Cumulus Neuroscience Ltd - Dublin (United Kingdom), ³Department of Clinical Neurosciences, University of Cambridge - Cambridge (United Kingdom), ⁴Nuffield Department of Clinical Neurosciences, University of Oxford - Oxford (United Kingdom)
- P184 Enhancing Automated Transcription for Speech-Based Screening in Alzheimer's Disease**
Udeepa Meepegama¹, Caroline Skirrow¹, Michael Ropacki², Emil Fristed¹, Jack Weston¹
¹Novoic - London (United Kingdom), ²Strategic Global Research & Development - Temecula (United States)
- P185 A Hybrid Deep Learning Audio-Visual Approach for Mild Cognitive Impairment Prediction: I-CONNECT Study**
Farida Far Poor¹, Muath Alsuhaibani¹, Mohammad H Mahoor¹, Liu Chen², Hiroko H Dodge²
¹Department of Electrical and Computer Engineering, University of Denver - Denver (United States), ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)
- P186 Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralised trials in Alzheimer's Disease**
Florentine Marie Barbey¹, Christopher J Barnum², Alison R Buick³, John Frederick Dyer³, Md Nurul Islam¹, Jack Fogarty⁴, Hugh Nolan¹, Brian Murphy¹
¹Cumulus Neuroscience Ltd. - Dublin (Ireland), ²INmune Bio Inc. - Boca Raton (United States), ³Cumulus Neuroscience Ltd. - Belfast (United Kingdom), ⁴Nanyang Technological University - Singapore (Singapore)
- P187 Accelerating Sustainable Adoption and Justification of Digital Clinical Detection Applications for Cognitive Impairment and Dementia into Established Healthcare Systems**
Ara Khachaturian¹, Brittany Cassin², Glen Finney³, Phyllis Barkman Ferrell⁴, Eric Klein⁴, Malaz Boustani⁵, Zaven Khachaturian¹
¹Campaign to Prevent Alzheimer's disease - Rockville (United States), ²DigiCARE Realized Inc. - Old Bridge (United States), ³Geisinger Health - Danville (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Indiana University - Indianapolis (United States)

- P189 Correlation between Altoida's digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers**
 Emmanuel Stree1, Adria Tort Merino 2, Alberto Ferrari 3, Gonzalo Sanchez-Benavides 4,5,6,7, Carolina Minguillon 4,5, Silvia Fallone Fallone 8, Robbert Harms 9, Ioannis Tarnanas 10, Mircea Balasa 2, M. Florencia Iulita 11
 1Altoida Inc. - Washington (United States), 2Hospital Clinic, IDIBAPS - Barcelona (Spain), 3Altoida Inc. - Rome (Italy), 4BarcelonaMeta Brain Research Center (BBRC) - Barcelona (Spain), 5Pasqual Maragall Foundation - Barcelona (Spain), 6Hospital del Mar Medical Research Institute - Barcelona (Spain), 7(CIBERFES), Instituto de Salud Carlos III - Madrid (Spain), 8Altoida Inc. - Maastricht (Netherlands), 9Altoida Inc. - Nijmegen (Netherlands), 10Altoida Inc. - Thessaloniki (Greece), 11Altoida Inc. - Barcelona (Spain)
- P190 Building an Evidence Catalog of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer's Disease and Related Dementias Clinical Trials**
 Sarah Averill Lott 1, Emmanuel Stree1, Piper Fromy 3, Jennifer Goldsack 4, On Behalf of The Dime Core Digital Measures Of ADRD Project Team 4
 1The Digital Medicine Society - Johnstown (United States), 2Altoida - Washington, DC (United States), 3The Digital Medicine Society - Saumur (France), 4The Digital Medicine Society - Boston (United States)
- P191 Advancing Computerized Cognitive Assessment: Cognivue's® Enhanced Normative Range Data Sets the New Gold Standard for Sensitivity and Patient Profiling**
 James Galvin 1
 1University of Miami Comprehensive Center for Brain Health - Boca Raton (United States)
- P192 The Brain Health Champion Study: A Health Coaching Intervention with Mobile Technology in Older Adults with Mild Cognitive Impairment or Risk Factors for Dementia- An Update**
 Kayla Riera 1, Ashley Park 1, Brittany MCFeeley 1, Demsina Babazadeh 1, Abby Altman 1, Kirk Daffner 1, Seth Gale 1
 1Brigham and Women's Hospital - Boston (United States)
- LP109 Development and clinical validation of icobrain aria – an AI-based assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities**
 Diana M. Sima 1, Thanh Vân Phan 1, Simon Van Eyndhoven 1, Sophie Verduyssen 1, Ricardo Magalhães 1, Celine Maes 1, Joshua Guo 2, Richard Hughes 2, Refaat Gabr 2, Paramita Saha-Chaudhuri 2, Gioacchino G Curiale 3, Shibeshih Belachew 2, Wim Van Hecke 1, Annemie Ribbens 1, Dirk Smeets 1
 1icometrix - Leuven (Belgium), 2Biogen Digital Health - Cambridge, Massachusetts (United States), 3Biogen - Cambridge, Massachusetts (United States)
- LP110 The Mobile ToolBox (MTB) as a novel outcome measure for assessing cognition remotely in Alzheimer's disease clinical trials: Validation with in-clinic cognitive assessments and AD biomarkers**
 Jessa Burling 1, Roos Jutten 1, Michael Properzi 1, Rebecca Amariglio 2, Gad Marshall 2, Kathryn Papp 2, Keith Johnson 3, Reisa Sperling 2, Dorene Rentz 2
 1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States), 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School & Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), 3Department of Neurology/Radiology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)
- LP111 Improving cognitive testing and care processes for older adults at risk of cognitive decline in a large health care system**
 Darren Gitelman 1,2,3, Jennifer Mishos 1, Cristybelles-Marie Canda 1, Patti Pagel 1,4, Lisa Dimitris 1, Michael Malone 1,4,5
 1Advocate Health, Neuroscience Service Line - Midwest Region - Downers Grove, IL (United States), 2Rosalind Franklin University of Medicine and Science, Department of Medicine - North Chicago, IL (United States), 3Northwestern University / Feinberg School of Medicine, Department of Neurology - Chicago, IL (United States), 4Aurora Health Care, Department of Senior Services - Milwaukee, WI (United States), 5University of Wisconsin School of Medicine & Public Health - Madison, WI (United States)
- LP112 Feasibility and acceptability of a remote and fully-automated phone screening for cognitive impairment in the Autonomy Phase II study**
 Simona Schäfer 1, Stephen Ruhmel 2, Johannes Tröger 1, David Henley 2, Felix Dörr 1, Jannic Warken 1, Nicklas Linz 1, Janna Herrmann 1, Kai Langel 2, Alexandra König 1
 1ki elements GmbH - Saarbrücken (Germany), 2Janssen Research & Development, LLC - Raritan (United States)
- LP113 Older people with mild cognitive impairment exhibit lower semantic noise after six months of frequent social conversations**
 Liu Chen 1, Meysam Asgari 1, Hiroko Dodge 2
 1Department of Pediatrics, Oregon Health & Science University - Portland (United States), 2Massachusetts General Hospital, Harvard Medical School - Boston (United States)
-  **LP114 Development and Preliminary Validation of a Virtual Reality Memory Test for Assessing Visuospatial Memory**
 Ko Woon Kim 1, Jong Doo Choi 2, Juhee Chin 3, Byung Hwa Lee 3, Choi Jee Hyun 4
 1Jeonbuk National University Medical School and Hospita - Jeonju (Korea, Republic of), 2Seers Technology Company Ltd - Seongnam (Korea, Republic of), 3Samsung Medical Center - Seoul (Korea, Republic of), 4Korea Institute of Science and Technology - Seoul (Korea, Republic of)
-  **LP115 Assessing the Impact of Donepezil on Visuospatial Abilities in Individuals with Mild Cognitive Impairment: A Preliminary Study Utilizing Eye-Tracking Metrics**
 Ko Woon Kim 1, Qi Wang 1, Byoung-Soo Shin 1
 1Kim - Jeonju (Korea, Republic of)

POSTER PRESENTATIONS

-  **LP116** **The Effect of Robot-Based Digital Cognitive Training on Cognitive Performance of Dementia Patients**
Jae Won Oh^{1,2}, Ji Hyun Lee³, Myeong Hun Hong⁴, Won Sub Kang⁵, Jong Woo Kim^{5,3}
¹Department of Neurology, Brigham and Women's Hospital - Boston, Massachusetts (United States), ²Whydots Inc. - Bucheon (Korea, Republic of), ³Department of Psychiatry, Kyung Hee University Hospital - Seoul (Korea, Republic of), ⁴Seodaemun-gu Center for Dementia - Seoul (Korea, Republic of), ⁵Department of Psychiatry, Kyung Hee University College of Medicine - Seoul (Korea, Republic of)
-  **LP117** **The digital literacy predicts the quality of life in normal old age group but not in dementia group**
Lee So-Yeong¹, Lim Jung-In¹, Lee Jun-Young^{1,2}
¹SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), ²Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of)
- LP131** **Observer-reported outcome of functional decline using continuous experience sampling: Findings from the RADAR-AD Study**
Sietske Sikkes^{1,2}, Merel Postema¹, Mukrabe Tewolde¹, Merike Verrijp³, Marijn Muurling¹, Casper De Boer¹, Srinivasan Vairavan⁴, Dag Aarsland⁵, Anna-Katharine Brem⁵, Gayle Wittenberg⁴, Mark Dubbelman⁶, Roos Jutten⁷, Philip Scheltens¹, Pieter Jelle Visser¹, Wiesje Van Der Flier¹
¹Amsterdam UMC - Amsterdam (Netherlands), ²VU University - Amsterdam (Netherlands), ³Brain Research Center - Amsterdam (Netherlands), ⁴Janssen Neuroscience R&D - Titusville, Nj (United States), ⁵Kings College London - London (United Kingdom), ⁶Brigham and Womens Hospital - Boston, Ma (United States), ⁷Harvard Medical School - Boston, Ma (United States)
- LP133** **A One-Stop-Shop for Telehealth Guided APOE Testing, Blood Based Biomarkers, and Multi-Domain Lifestyle Intervention: Early Learnings From a Proof-of-Concept**
Anitha Rao¹, Leyla Anderson¹, Travis Wilkes¹, Steven Verdooner¹
¹Neurovision Inc - Sacramento (United States)

THEME: Beyond Amyloid and Tau

-  **P193** **Angiogenic Mechanisms in Alzheimer's Disease: A Systematic Review of Neuropathological Evidence**
Arunima Kapoor¹, Daniel Nation¹
¹University of California, Irvine - Irvine (United States)
- P194** **Do Mouse Data Lie? For Buntanetap They Totally Predict Human Outcomes All the Way to Clinical Efficacy**
Maria Maccacchini¹, Cheng Fang¹
¹Annovis Bio - Berwyn (United States)
- P195** **Fluid Biomarker Results from an Open-Label Pilot Study of Senolytic Therapy for Alzheimer's Disease, StoMP-AD**
Miranda E. Orr^{1,2,3}, Valentina R Garbarino^{4,5}, Juan Pablo Palavicini⁴, Tiffany F. Kautz^{4,5}, Shiva K Dehkordi^{6,5}, Habil Zare^{6,5}, Peng Xu^{7,8}, Bin Zhang^{7,8}, Justin Melendez^{9,10}, Nicolas Barthelemy^{9,10}, Randall J Bateman^{9,10}, Mitzi M Gonzales^{11,5}
¹Wake Forest University School of Medicine, Gerontology and Geriatric Medicine, - Winston-Salem (United States), ²Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States), ³Salisbury VA Medical Center - Salisbury (United States), ⁴University of Texas Health Science Center at San Antonio, Department of Medicine, - San Antonio (United States), ⁵Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases - San Antonio (United States), ⁶University of Texas Health Science Center at San Antonio Department of Cell Systems and Anatomy, - San Antonio (United States), ⁷Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, - New York (United States), ⁸Mount Sinai Center for Transformative Disease Modeling - New York (United States), ⁹Washington University School of Medicine, Department of Neurology - St Louis (United States) - St Louis (United States), ¹⁰The Tracy Family SILQ Center - St Louis (United States), ¹¹University of Texas Health Science Center at San Antonio, Department of Neurology - San Antonio (United States)
- P196** **Plasma and cerebrospinal fluid proteomic association during Alzheimer's disease (AD) progression suggests possible new targets for treating AD patients**
Ying Wang¹, Ricardo Gonzalo², Carla Minguet², Ana Maria Ortiz², Scott Lohr¹, Mercè Boada³, Oscar López⁴, Antonio Paez², Jorge Loscos⁵, Jesús Canudas⁵, María Pascual⁵, Jose Terencio², Montserrat Costa², Chunmiao (mia) Feng¹, Benoit Lehallier¹
¹Alkhest, a Grifols company - San Carlos (United States), ²Grifols - Barcelona (Spain), ³Universitat Internacional de Catalunya - Barcelona (Spain), ⁴University of Pittsburgh - Pittsburgh (United States), ⁵Araclon, a Grifols company - Zaragoza (Spain)
- P197** **Whole transcriptomic cell free messenger RNA characterization of Alzheimer's disease in cerebrospinal fluid compared to plasma from human subjects**
Rhys De Sota¹, Robert Rissman², James Brewer², Samantha Khoury¹, Shusuke Toden¹, John Sninsky¹
¹Molecular Stethoscope - South San Francisco (United States), ²University of California, San Diego - San Diego (United States)



- P198 CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease**
 Charlotte Teunissen¹, Emma L. Van Der Ende², Sjors In 't Veld², Iris Hanskamp², Sven Van Der Lee^{3,4}, Janna Dijkstra⁵, John C. Van Swieten⁶, David J. Irwin⁷, Alice Chen-Plotkin⁷, William T. Hu⁸, Afina Lemstra⁹, Yolande A.L. Pijnenburg⁹, Wiesje M. Van Der Flier^{9,10}, Marta Del Campo^{9,11}, Lisa Vermunt^{2,9}
¹Amsterdam UMC - Amsterdam (Netherlands), ²Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ³Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁴Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Pays-Bas) - Amsterdam (Netherlands), ⁵Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁶Alzheimer Center and Department of Neurology, Erasmus University Medical Center - Rotterdam (Netherlands), ⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), ⁸Department of Neurology, Emory University School of Medicine - Atlanta (United States), ⁹Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ¹⁰Department of Epidemiology and Data Science, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ¹¹Barcelonabeta Brain Research Center (BBRC) - Barcelona (Spain)
- P199 Lipid Dicarboxyl Scavengers for the Prevention of Alzheimer's Disease**
 John A. Rathmacher¹, Naji N. Abumrad², Paul A. Newhouse²
¹MTI BioTech Inc - Ames (United States), ²Vanderbilt University Medical Center - Nashville (United States)
- P200 Translation Studies and Clinical Development of THN391, a Novel Anti-Fibrin Antibody for the Treatment of Dementia**
 Jeffrey Stavenhagen¹, Mathias Rickert¹, Kenneth Flanagan¹, Hank Cheng¹, Anjana Suppahia¹, Vasudha Salgotra¹, Jae Kyu Ryu², Katerina Akassoglou²
¹Therini Bio - San Francisco (United States), ²Gladstone Institute - San Francisco (United States)
- P201 The temporal relationship between neuropsychiatric symptoms, physical activity, and sleep: A three cohort-study**
 Adrian Noriega De La Colina¹, Meishan Ai², Nikolaos Scarmeas³, Arthur F. Kramer², Maiya R. Geddes¹
¹Department of Neurology and Neurosurgery, The Montreal Neurological Institute-Hospital, McGill University - Montreal (Canada), ²Center for Cognitive and Brain Health, Department of Psychology, Northeastern University - Boston (United States), ³1st Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens - Athens (Greece)
- P202 Cerebrospinal Fluid Proteomic Analysis Reveals Reversal Effects on Glucose Dysmetabolism in Alzheimer's Disease after Treatment with Atomoxetine**
 Eric Dammer¹, Lingyan Ping¹, Duc Duong¹, Erica Modeste¹, Nicholas Seyfried¹, James Lah¹, Allan Levey¹, Erik Johnson¹
¹Emory University - Atlanta (United States)
- P203 Blood-Based small RNA Biomarkers and the ATN(V) Framework: Predicting Neurodegeneration and Vascular Profiles in the EPAD Cohort**
 Bruno Steinkraus¹, Marco Heuvelman¹, Luigi Lorenzini², Julia Jehn¹, Tobias Sikosek¹, Rastislav Horos¹, Kaja Tikk¹, Jeffrey Cummings³, Jean Manson⁴, Craig Ritchie⁴
¹Hummingbird Diagnostics GmbH - Heidelberg (Germany), ²Amsterdam University Medical Center - Amsterdam (Netherlands), ³Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas - Las Vegas (United States), ⁴Centre for Clinical Brain Sciences, The University of Edinburgh - Edinburgh (United Kingdom)
- P204 Evaluation of GLP-1 analogue, Liraglutide in the treatment of Alzheimer's disease**
 Paul Edison¹
¹Imperial College London - London (United Kingdom)
- LP118 An open-label, pilot study of daratumumab SC in patients with mild to moderate Alzheimer's disease (DARZAD)**
 Marc Gordon^{1,2}, Erica Christen¹, Lynda Keehlisen¹, Michelle Gong¹, Fung Lam³, Luca Giliberto^{1,4}, Jesus Gomar¹, Jeremy Koppel^{1,5}
¹Litwin-Zucker Research Center, Feinstein Institutes for Medical Research, Northwell Health - Manhasset, New York (United States), ²Departments of Neurology and Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell - Hempstead, New York (United States), ³Feinstein Institutes for Medical Research, Northwell Health - Manhasset, New York (United States), ⁴Institute for Neurology and Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell - Great Neck, New York (United States), ⁵Department of Psychiatry, Zucker Hillside Hospital, Northwell Health - Glen Oaks, New York (United States)
-  **LP119 Association of Serum Leptin with in vivo brain Alzheimer's disease pathologies in cognitively normal older adults**
 Seunghoon Lee¹, Min Soo Byun^{2,3}, Dahyun Yi⁴, Dongyoung Lee^{2,3,4}
¹Department of Psychiatry, Myongji hospital, Hanyang University College of Medicine - Goyang (Korea, Republic of), ²Department of Neuropsychiatry, Seoul National University Hospital - Seoul (Korea, Republic of), ³Department of Psychiatry, Seoul National University College of Medicine, - Seoul (Korea, Republic of), ⁴Institute of Human Behavioral Medicine, Medical Research Center Seoul National University - Seoul (Korea, Republic of)
-  **LP120 Misfolding Of Biomarkers Stratifies Proteinopathies**
 Klaus Gerwert¹
¹Ruhr-University Bochum - Bochum (Germany)